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Abstract 
 
 Worldwide, more than 35 million people are currently infected with the human 
immunodeficiency virus (HIV). Approximately half of HIV-infected patients in the U.S. 
experience cognitive impairment despite effective control of viral load with combination 
anti-retroviral therapy (cART). The neurological complications that stem from an HIV 
infection are known as HIV-associated neurocognitive disorders (HAND). HAND ranges 
in severity from subtle difficulties with day-to-day tasks to severe functional impairment 
requiring assistance to survive. Although cART has improved patient survival by 
effectively managing viral load, it is ineffective at treating the majority of HAND. 
Consequently, the prevalence of HAND remains persistently high.  
 The symptoms of HAND correlate with neuronal damage, such as synapse loss 
and dendritic beading. Such synaptodendritic damage results from HIV-infected cells 
within the central nervous system (CNS) shedding neurotoxic agents, such as the HIV-1 
protein transactivator of transcription (Tat). Tat potentiates N-methyl D-aspartate 
(NMDA) receptor function allowing excessive Ca2+ influx leading to neurotoxicity. In 
this dissertation, two studies are outlined investigating the mechanisms of NMDA 
receptor (NMDAR) dysfunction following exposure to Tat.  The graphical abstract 
summarizes these studies. 
 First, the effect of Tat on NMDAR function was investigated. This study showed 
that Tat caused a time-dependent, biphasic change in NMDAR function. Initially, Tat 
potentiated NMDAR function via the low-density lipoprotein receptor-related protein 
(LRP) and activation of Src tyrosine kinase. Subsequently, NMDAR function adapted by 
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gradually returning to basal levels following 24 h exposure to Tat and eventually falling 
below control responses by 48 h. Adaptation resulted from activation of a nitric oxide 
synthase (NOS), soluble guanylate cyclase (sGC), cGMP-dependent protein kinase 
(PKG) signaling pathway.   
 Next, effectors downstream of PKG responsible for adaptation of NMDAR 
function were identified. Tat activated a signaling pathway including the small GTPase 
RhoA and Rho-associated protein kinase (ROCK). RhoA/ROCK activation caused 
remodeling of the actin cytoskeleton resulting in reduced NMDAR function.  
Taken together, these studies indicate that Tat causes a biphasic change in 
NMDAR function. Potentiation of NMDAR function is mediated by LRP-dependent 
activation of Src kinase; adaptation of NMDAR function occurs after activation of a 
NOS/sGC/PKG signaling pathway leading to RhoA/ROCK-mediated remodeling of the 
actin cytoskeleton. Adaptation of NMDAR function may be a neuroprotective 
mechanism to reduce excess Ca2+ influx and prevent neurotoxicity. These studies provide 
molecular and temporal detail of the dynamic changes in NMDAR function following 
exposure to Tat and offer insight into potential therapeutic targets for the treatment of 
HAND. 
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Graphical Abstract 
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Graphical abstract. 
a, Stylized traces ( ) illustrate NMDA-evoked Ca2+ influx following treatment with Tat 
for the time indicated above the trace. Tat-induced potentiation begins following 2 h 
exposure and peaks by 8 h. Subsequently, NMDA-evoked Ca2+ responses begin to adapt 
by gradually returning to basal levels by 24 h and dropping below control responses by 
48 h. b, Proposed mechanism of Tat-induced biphasic change in NMDAR function. Tat 
interacts with the LRP leading to Src kinase-mediated potentiation of NMDAR function 
that then adapts after activation of a NOS/cGMP/PKG signaling pathway resulting in 
RhoA/ROCK-mediated remodeling of the actin cytoskeleton and reduction of NMDAR 
function. Solid and dashed arrows represent direct and potentially indirect connections, 
respectively. 
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I. HIV pathogenesis and virology  
Human immunodeficiency virus  (HIV) is the causal agent of acquired 
immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo et al., 1984; 
Popovic et al., 1984; Sarngadharan et al., 1984; Schupbach et al., 1984) and is one of the 
deadliest diseases in history. HIV has infected more than 70 million people resulting in 
more than 35 million AIDS-related deaths (WHO Global Health Observatory, 2014). 
Today, approximately 35 million people are infected with HIV (UNAIDS, 2013) and 
despite improved prevention programs and pharmacotherapy, the pandemic is far from 
over.  
 The transmission of HIV occurs by exchange of bodily fluids commonly 
occurring via sexual intercourse with a host (U.S. Dept. of Health and Human Services, 
2014c). Flu-like symptoms such as fever, fatigue, and rash begin within days to weeks of 
infection with HIV and persist for up to 10 weeks (Kahn and Walker, 1998). Symptoms 
of acute HIV infection rarely lead to an accurate diagnosis, as patients are usually 
unaware of the exposure. However, HIV can be detected as within 2 weeks of infection 
(Cohen et al., 2010). Eventually, the acute symptoms subside as the disease progresses to 
clinical latency, which can persist an average of 10 years, although the rate of progression 
varies dramatically between individuals (U.S. Dept. of Health and Human Services, 
2014b). During clinical latency and without treatment, HIV depletes the immune system 
of CD4-positive lymphocytes to below 200 cells/mm3 resulting in progression of the 
disease from HIV to AIDS (U.S. Dept. of Health and Human Services, 2014b). Typically, 
people with AIDS die within three years without antiretroviral therapy (U.S. Dept. of 
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Health and Human Services, 2014b). Compromised immune function renders the patient 
increasingly vulnerable to opportunistic infections (OI) such as pneumocystis carinii 
pneumonia, tuberculosis, toxoplasmosis, cryptococcus neoformans, and progressive 
multifocal leukoencephalopathy (Kaplan et al., 2000; Sepkowitz, 2002). The average life 
expectancy of a person with AIDS with an OI is one year (Walensky et al., 2006; U.S. 
Dept. of Health and Human Services, 2014b). Such severe immunosuppression impairs 
nearly all organ systems including the central nervous system (CNS) (Chu and Selwyn, 
2011). 
 HIV-1 belongs to the family Retroviridae, subfamily Lentivirinae, and genus 
Lentivirus (Votteler, 2008). Each virion of HIV-1 contains two ribonucleic acid (RNA) 
strands approximately 9.7 kilobases in length (Votteler, 2008). Each RNA strand encodes 
nine viral genes including gag, env, pol, vpu, vif, vpr, nef, rev, and tat. These genes 
encode proteins that fall in into structural (gag, env), catalytic (pol), accessory (vpu, vif, 
vpr, nef), or regulatory (rev, tat) classes (Votteler, 2008). Additionally, each virion 
contains three essential enzymes necessary for viral replication, including reverse 
transcriptase (Chandra et al., 1986), integrase (Stevenson et al., 1990), protease 
(Schneider and Kent, 1988), and two viral RNA strands (Feinberg et al., 1986).  The 
nucleocapsid of HIV, composed of the core capsid protein p24 (Gelderblom et al., 1987), 
encases the viral contents (Wills and Craven, 1991; Dorfman et al., 1994). The viral 
envelope, composed of a lipid bilayer formed during budding from the membrane of the 
infected host cell, surrounds the nucleocapsid. Embedded within the viral envelope are 
the surface proteins gp120 (Barin et al., 1985) and gp41 (Veronese et al., 1985).  
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HIV is an obligate intracellular parasite requiring human cells for replication. 
Viral tropism is determined by the cell surface protein gp120 (Chan et al., 1997; Berger 
et al.), which is essential for viral infection of the host cells. Infection with HIV occurs 
when gp120 binds to CD4 receptors (Dalgleish et al., 1984; Kwong et al., 1998) and 
either co-receptor CXCR4 (Feng et al., 1996; Lapham et al., 1996) or CCR5 (Wu et al., 
1996).  Subsequently, gp41 undergoes a conformational change resulting in the insertion 
of the N-terminal hydrophobic fusion-peptide into the membrane of host cell (Furuta et 
al., 1998). Next, gp41 collapses into a trimer-of-hairpins that pulls the virus closer to the 
cell until the two eventually fuse (Gonzalez-Scarano et al., 1987; Root et al., 2001).   
Fusion enables the viral contents to spill into the cytoplasm of the host cell where the 
process of viral replication can begin. Viral RNA generates viral DNA by reverse 
transcription (Preston et al., 1988; Roberts et al., 1988). Viral DNA is transported into the 
nucleus of the host cell and integrated into the host cell genome by the viral enzyme, 
integrase (Bukrinsky et al., 1992). Integrated HIV is a provirus. Proviral DNA is 
transcribed into HIV RNA as part of normal cellular genomic activity. HIV RNA 
transcripts are translated into immature viral polypeptides; protease assists in the 
maturation of immature polypeptides into their functional forms via proteolysis (Greene 
and Peterlin, 2002). Following replication of all necessary viral components, they are 
packaged into the nucleocapsid, which buds from the host cell membrane to form a new 
viral particle in search of other cells to infect (Greene and Peterlin, 2002).   
Two types of HIV are known to exist: HIV-1 and HIV-2, although HIV-1 
accounts for the majority of infections worldwide (McCutchan, 2006). HIV-1 and -2 
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differ in the zoonotic origin with HIV-1 most closely resembling simian 
immunodeficiency virus from chimpanzees (Huet et al., 1990) whereas HIV-2 appears to 
have originated in the sooty mangabey (Hirsch et al., 1989). HIV-1 is more virulent, 
results in higher viral loads, and has a greater rate of disease progression relative to HIV-
2 (Marlink et al., 1994). HIV-1 is divided into three groups: Main (M), Outlier (O), and 
Non-M, Non-O (N) (McCutchan, 2006). The M-group constitutes the majority of 
infections worldwide whereas the O- and N-group are rare and mostly confined to the 
African country of Cameroon (McCutchan, 2006). The M-group is subdivided into nine 
clades; A through K, with clades B and C being the most common global subtypes 
(McCutchan, 2006). Interestingly, the induction of neuropathogenesis is clade-dependent 
with clade B being more neurotoxic than clade C (Rao et al., 2008).  
 
II. Treatment of HIV  
HIV infection has no known cure, however the efficacy of pharmacotherapy has 
improved dramatically in the past 30 years (Heaton et al., 2011). Consequently, HIV has 
been transformed from a fatal infection to a manageable condition due to combination 
antiretroviral therapy (cART).  The use of cART as standard therapy began 1996 and has 
remained the recommended treatment for HIV infection ever since (U.S. Dept. of Health 
and Human Services, 2014a). Therapeutic regimens consist of combinations of at least 
three antiretroviral drugs including viral fusion inhibitors, nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease 
inhibitors, and integrase inhibitors (U.S. Dept. of Health and Human Services, 2014a). 
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Drugs within these respective classes target distinct steps in the viral replication cycle 
and have been instrumental for the treatment and management of HIV. Combination 
therapy improves patient outcomes by reducing peripheral viral load and decreasing 
opportunistic infections thereby increasing patient survival (Kaplan et al., 2000; Hogg, 
2008).  
While current-generation cART effectively reduces peripheral viral load and 
prolongs the lifespan of the patient, viral reservoirs persist within the central nervous 
system (CNS) (Lambotte et al., 2003). These latent viral reservoirs persist in the brain 
due to insufficient drug distribution to the CNS, inadequate treatment, decreased 
effectiveness of cART, and other factors that contribute to the persistently high 
prevalence of HIV-associated neurocognitive disorders (HAND) (Valcour et al., 2011).  
 
III. HIV-associated neurocognitive disorders  
HIV enters the CNS as early as 2 weeks following the initial infection (Resnick et 
al., 1988; Davis et al., 1992; An et al., 1999). Multiple pathways have been proposed for 
how HIV enters the CNS. The “Trojan Horse” hypothesis suggests that HIV enters the 
CNS undetected by hiding inside monocytes or CD4+ T-cells, which routinely traffic into 
the CNS (Peluso et al., 1985; Nath, 1999). Alternatively, HIV crosses the endothelial 
cells of the blood-brain barrier (BBB) by transcytosis to enter the CNS (Bomsel, 1997; 
Banks et al., 2004).  Once inside the CNS, HIV causes neurotoxicity leading to HAND 
(Clifford and Ances, 2013). HAND affects approximately half of the HIV-infected 
patients in the U.S. and it is likely that the prevalence is higher in regions of the world 
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where cART is uncommon. Thus, up to half of the 35 million patients infected with HIV 
are at risk of developing HAND (Cysique et al., 2004; Tozzi et al., 2005; Heaton et al., 
2011). Symptoms of HAND are categorized based on the severity of impairment and 
range from subtle impairment in day-to-day tasks to severe functional impairment 
(Heaton et al., 2004; Antinori et al., 2007). The prevalence of asymptomatic 
neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-
associated dementia (HAD) vary depending on the stage of HIV disease, but constitute 
approximately 20%, 20%, and 8% of the HIV-infected population in the U.S.A, 
respectively (Antinori et al., 2007). Patients with ANI have subtle impairment in at least 
two ability domains with no impairment in day-to-day functioning (Antinori et al., 2007). 
Patients with MND have modest impairment in at least two ability domains and have 
mild cognitive decline resulting in impaired day-to-day functioning (Antinori et al., 
2007). Patients suffering from HAD exhibit marked impairment in cognitive function 
with significant difficulty performing day-to-day tasks (Antinori et al., 2007). The pre-
cART prevalence of HAD was 4%, 12%, and 17% for the respective CDC stages of HIV 
disease A, B, and C (Heaton et al., 2011). However, in the cART era, the prevalence of 
HAD is approximately 8% across all disease stages (Heaton et al., 2011). Unfortunately, 
the prevalence of all other forms of HAND remains persistently high despite effective 
control of viral load with cART (Heaton et al., 2010).  
The persistence of HAND is thought to arise, at least in part, from latent viral 
reservoirs within the CNS that are not entirely accessible to current-generation cART 
(Valcour et al., 2011).  Anti-retroviral therapies with higher CNS penetration 
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effectiveness (CPE) scores significantly improve cognitive function in patients with 
HAND relative to HAND patients receiving drugs with lower CPE scores (Cysique et al., 
2009). These data indicate that reducing or eradicating viral reservoirs using therapies 
with improved CNS penetrance may reduce the prevalence of HIV-associated cognitive 
impairment. In recent years, adjunctive therapies to treat HIV-associated cognitive 
impairment have gained significant interest. Some of these drugs include the anti-
epileptic, valproic acid (Schifitto et al., 2006), the monoamine oxidase inhibitor, 
selegiline (Sacktor et al., 2000; Evans et al., 2007; Schifitto et al., 2007a), the glycogen 
synthase kinase 3-beta inhibitor, lithium (Letendre et al., 2006; Schifitto et al., 2009), the 
calcium channel blocker, nimodipine (Navia et al., 1998), and the NMDAR antagonist, 
memantine (Schifitto et al., 2007b; Zhao et al., 2010). A meta-analysis investigated the 
efficacy of 10 promising adjunctive therapies in treating cognitive impairment in HAND 
patients and determined that these drugs are ineffective at treating or preventing HAND 
(Uthman and Abdulmalik, 2008). These data highlight the importance of improving the 
distribution of cART to the CNS and enhancing our understanding of the 
pathophysiological mechanisms that cause HAND so that targeted CNS therapies can be 
developed.   
 Another reason for the persistence of HAND is due to prolonged lifespans of 
patients resulting from successful cART regimens. Aging HIV+ patients are especially 
susceptible to cognitive decline (Valcour et al., 2004). By 2015, over half of the HIV+ 
population of the United States will be over the age of 50 placing them at increased risk 
for the development of HAND (Adekeye et al., 2012). Thus, while the HIV+ population 
    
 
 
9 
continues to grow and age, very few options are available to treat or prevent the HIV-
associated cognitive decline they are likely to develop. In order to develop new therapies 
or use existing treatments against HIV-associated cognitive decline, an enhanced 
understanding of the underlying mechanisms causing cognitive impairment is required. 
 
IV. Mechanisms of HIV-associated neurotoxicity  
Cells expressing CD4 receptors and either CXCR4 or CCR5 co-receptors are 
susceptible to HIV infection (Dalgleish et al., 1984; Feng et al., 1996; Lapham et al., 
1996; Wu et al., 1996; Kwong et al., 1998). Cells within the CNS such as microglia 
(Albright et al., 1999) and perivascular macrophages (Williams et al., 2001) express these 
receptors, but neurons do not. Thus, HIV is unable to infect neurons indicating that HIV-
induced neuronal damage is indirect (Wiley et al., 1986; Gonzalez-Scarano and Martin-
Garcia, 2005). As shown in Figure 1.1, HIV-infected cells can release a variety of agents 
that are neurotoxic including inflammatory cytokines (Genis et al., 1992), nitric oxide 
(Eugenin et al., 2007), glutamate (Jiang et al., 2001), as well as the viral proteins, gp120 
(Schneider et al., 1986) and Tat (Chang et al., 1997). 
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Figure 1.1: Mechanisms of glutamate excitoxicity during HIV-1 infection                 
(1) Infection of circulating monocytes with HIV-1. (2) HIV-1 infected macrophages cross 
the BBB and become perivascular macrophages. (3) HIV-1 infected perivascular 
macrophages in the brain parenchyma release viral particles that infect other brain 
macrophages and microglial cells. (4) Activated macrophages and microglial cells release 
viral proteins gp120 and Tat, glutamate and other factors such as NO, ROS, cytokines, 
chemokines and arachidonic acid that can either directly or indirectly affect glutamate 
metabolism and/or transport. (5) Decrease in glutamate uptake by oligodendrocytes and 
astrocytes due to increased levels of these toxins released by HIV-1 infected 
macrophages and microglial cells. These factors also cause an increase in vesicular 
glutamate release by astrocytes. (6) Viral proteins Tat and gp120 and oxidative stress 
induced by ROS and NO cause an increase in the activity of glutamate-cystine antiporter 
in uninfected perivascular macrophages and microglia and as a consequence extracellular 
levels of glutamate increase. (7) Excessive extracellular glutamate triggers activation of 
glutamate receptors on neurons causing an increase in the intracellular calcium levels, 
cell death and neuronal degeneration (Potter et al., 2013). Reproduced with permission, © 
2013 Springer  
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These agents create a neurotoxic environment resulting in disrupted Ca2+ homeostasis, 
synaptodendritic damage, and cell death (Kaul et al., 2001). Although cell death is 
observed in the brains of patients who succumbed to HIV/AIDS, the extent of cell death 
does not correlate closely with cognitive decline. Rather, symptoms of cognitive 
impairment correlate better with damage to synaptodendritic structures, including loss of 
dendritic spine density and dendritic beading (Ellis et al., 2007). Symptoms of cognitive 
impairment that result from synaptodendritic damage include memory loss, difficulty 
with comprehension, and reduced information processing speed (Heaton et al., 2004; 
Antinori et al., 2007). Additionally, HIV causes motor deficits (Arendt et al., 1990) and 
psychiatric disorders (Atkinson et al., 1988). Intriguingly, in vitro studies indicate that the 
synaptodendritic damage thought to give rise to cognitive impairment is preventable, and 
in some instances, reversible (Kim et al., 2008; Shin et al., 2012; Hargus and Thayer, 
2013). Thus, it may be possible to preserve cognitive function in HIV+ patients with the 
appropriate therapy. 
 
V. HIV-1 Tat: A potent neurotoxin  
 
 HIV-infected cells can release many substances that contribute to HAND (Potter 
et al., 2013). Although the neuropathogenesis of HAND likely involves a combination of 
factors, evidence suggests that the HIV protein transactivator of transcription (Tat) plays 
a prominent role in neurotoxicity (Shin et al., 2012) and cognitive impairment (Fitting et 
al., 2010; Carey et al., 2012; Bachani et al., 2013; Fitting et al., 2013).  
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Tat is a nonstructural viral protein that is responsible for initiating transcription of 
the HIV genome (Sodroski et al., 1985a; Sodroski et al., 1985b).  After activation of 
genomic transcription, Tat binds to the trans-activation response region (Berkhout et al., 
1989; Dingwall et al., 1990) and forms a complex with transcriptional machinery 
including RNA polymerase II, cyclin T1 and cyclin-dependent kinase 9 (CDK9) (Isel and 
Karn, 1999). Cyclin T1 activates CDK 9 to phosphorylate RNA polymerase II leading to 
transcription of the HIV-1 genome.  
 Tat is encoded by two exons; the first exon encodes amino acids 1-72 while the 
second exon encodes amino acids 73-104 (Kuppuswamy et al., 1989; Ruben et al., 1989; 
Romani et al., 2010). The first exon contains domains that are essential for Tat’s 
neurotoxic properties and transactivation abilities. Domains 1 through 3, known as the 
activation domain, consist of the N-terminal domain, a cysteine-rich domain, and the core 
domain. The fourth domain aids in the nuclear localization of Tat, while the fifth domain 
is required for transactivation. The second exon encodes a basic, C-terminal region that is 
critical for cellular uptake of Tat (Ma and Nath, 1997).    
Tat is shed from HIV-infected cells (Chang et al., 1997) and detected in the CNS 
of HIV-infected patients (Chang et al., 1997; Hudson et al., 2000).  The level of anti-Tat 
antibodies in the CSF of HIV-infected patients is higher in patients without cognitive 
impairment and lower in patients with cognitive decline suggesting antibody responses 
against Tat may preserve cognitive function (Bachani et al., 2013). Despite significant 
improvement in the efficacy of cART for treating HIV infection, current regimens remain 
unable to halt the production of Tat once viral DNA is integrated into the host genome 
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(Li et al., 2009). In vivo, expression of Tat causes loss of dendritic spines and 
synaptodendritic damage resulting in learning and memory impairment (Fitting et al., 
2010; Carey et al., 2012; Fitting et al., 2013). In vitro, Tat directly depolarizes neurons 
(Cheng et al., 1998), potentiates NMDA receptor (NMDAR) function (Haughey et al., 
2001; Krogh et al., 2014), and disrupts intracellular Ca2+ ([Ca2+]i) homeostasis (Haughey 
et al., 1999). Additionally, Tat causes loss of excitatory synapses (Kim et al., 2008) and 
presynaptic terminals (Shin and Thayer, 2013), inhibitory synapse gain (Hargus and 
Thayer, 2013), and neuronal death (Eugenin et al., 2007; Shin et al., 2012). Cognitive 
decline in HAND correlates more closely with synaptodendritic damage, which occurs 
prior to neuronal cell death (Ellis et al., 2007). Intriguingly, synaptic changes observed in 
vitro that precede neuronal death are reversible (Kim et al., 2008; Shin et al., 2012; 
Hargus and Thayer, 2013). Importantly, almost all instances of Tat-induced neurotoxicity 
are prevented by pharmacologic inhibition of the NMDAR (Eugenin et al., 2007; Kim et 
al., 2008; Shin et al., 2012; Hargus and Thayer, 2013) indicating that Tat-induced 
neurotoxicity requires aberrant NMDAR-mediated Ca2+ influx. Thus, enhanced 
understanding of the mechanisms leading to NMDAR dysfunction and the consequences 
of abnormal receptor function are a major focus for the development of improved HAND 
therapies. 
   
VI. NMDA RECEPTORS  
The NMDAR is an ionotropic glutamate receptor expressed in neurons 
(McLennan, 1983).  Activation of NMDARs requires coincident cellular depolarization 
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to relieve the Mg2+ block of the ion channel (Nowak et al., 1984) and binding of both 
glutamate (Jahr and Stevens, 1987) and glycine (Johnson and Ascher, 1987) to ligand 
binding sites. NMDAR activation causes the channel to open allowing an influx of Ca2+ 
into the neuron (MacDermott et al., 1986). The NMDAR is composed of two obligatory 
GluN1 subunits and two regulatory GluN2 subunits to form a tetramer (Cull-Candy et al., 
2001). Four distinct GluN2 isoforms have been identified and include GluN2A, GluN2B, 
GluN2C, and GluN2D (Cull-Candy et al., 2001).  Each tetramer has distinct properties; 
GluN2A- and GluN2B-containing NMDARs have high channel conductance openings, 
while NMDARs containing GluN2C and GluN2D have low channel conductance 
openings (Cull-Candy and Leszkiewicz, 2004). Additionally, deactivation kinetics are 
most rapid in NMDARs containing GluN2A, slowest in GluN2D-containing NMDARs, 
and equal between GluN2B- and GluN2C-containing NMDARs (Cull-Candy and 
Leszkiewicz, 2004). The hippocampus only expresses NMDARs containing GluN2A and 
GluN2B (Wenzel et al., 1997) that localize to synaptic and extrasynaptic regions of the 
neuron, respectively (Groc et al., 2006; Hardingham and Bading, 2010).  
The NMDAR is an essential component in the synaptic machinery that underlies 
learning and memory. Overexpression or pharmacologic inhibition of NMDARs results 
in improved (Tang et al., 1999) or impaired (Malhotra et al., 1996; Newcomer and 
Krystal, 2001) cognitive function, respectively. NMDAR dysfunction is implicated in 
many neurodegenerative disorders including Alzheimer’s (Danysz and Parsons, 2003) 
and Parkinson’s (Hallett and Standaert, 2004) disease, amyotrophic lateral sclerosis 
(Spalloni et al., 2013), multiple sclerosis (Rossi et al., 2013), Huntington’s disease 
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(Young et al., 1988), and HAND (Kaul et al., 2001; Potter et al., 2013). Although many 
neurodegenerative diseases are etiologically distinct, they share a common feature: 
NMDAR dysfunction. Tat causes NMDAR dysfunction (Haughey et al., 2001; Chandra 
et al., 2005; Li et al., 2008; Krogh et al., 2014) likely contributing to the symptoms of 
cognitive impairment in HAND patients. 
  
VII. The role of NMDA receptors in Tat-induced neurotoxicity 
Treatment with Tat affects NMDARs directly and indirectly. Tat directly activates 
the NMDAR (Song et al., 2003) resulting in neurotoxicity (Li et al., 2008). Additionally, 
Tat indirectly enhances NMDAR function via binding to and relieving the inhibitory 
effect of Zn2+ (Chandra et al., 2005) or via tyrosine kinase-mediated phosphorylation of 
NMDARs (Haughey et al., 2001). NMDAR-mediated Ca2+ influx leads to loss of 
excitatory synapses via ubiquitination and subsequent proteasomal degradation of the 
postsynaptic scaffolding protein 95 (PSD-95) by an E3 ligase-dependent mechanism 
(Kim et al., 2008). Distinct intracellular signaling pathways are activated depending on 
the NMDAR subtype mediating the Ca2+ influx (Hardingham et al., 2002). 
Pharmacologic blockade of GluN2A-containing NMDARs prevents Tat-induced synapse 
loss, but does not block Tat-induced cell death. Conversely, inhibition of GluN2B-
containing NMDARs prevents Tat-induced cell death, but is ineffective at preventing 
Tat-induced synapse loss. Intriguingly, antagonism of GluN2B-containing NMDARs 
induces synapse recovery in the presence of Tat after synapse loss has already occurred 
(Shin et al., 2012). Thus, NMDAR subtypes differentially participate in adaptive 
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processes following exposure to Tat. Concurrent with excitatory synapse loss, NMDAR-
mediated Ca2+ influx also increases the number of inhibitory synapses via a calmodulin-
dependent protein kinase II (CAMKII)-dependent process (Hargus and Thayer, 2013). 
Lastly, Tat causes neuronal cell death via NMDAR-dependent production of nitric oxide 
(NO) (Eugenin et al., 2007). Thus, Tat-induced changes in synaptic composition and cell 
death require NMDAR-mediated Ca2+ influx. 
 
VIII. Summary of introduction and current studies  
 The pandemic of HIV is far from over, but major progress in the detection, 
treatment, and management of this condition has been made. Anti-retroviral drugs have 
transformed HIV infection from a fatal disease to a manageable condition (Hogg, 2008), 
but the prevalence of HAND remains persistently high is likely to increasing due to 
prolonged lifespans of patients (Heaton et al., 2011).  In order to develop new therapies 
or make use of existing treatments, an enhanced understanding of the mechanisms 
leading to HIV-associated cognitive impairment is required. Cognitive impairment stems 
from synaptodendritic damage (Ellis et al., 2007); a significant cause of such 
neurotoxicity is excessive Ca2+ influx through the NMDAR (Shin et al., 2012). The 
subject of this dissertation is the mechanism responsible for NMDAR dysfunction 
following exposure to the HIV-1 protein, Tat.  
 Tat is a potent neurotoxin that damages neurons (King et al., 2006) and causes 
cognitive impairment (Fitting et al., 2010; Carey et al., 2012). Tat causes loss of 
excitatory synapses (Kim et al., 2008), simultaneous gain of inhibitory synapses (Hargus 
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and Thayer, 2013), and neuronal death (Shin et al., 2012). Cell death and changes in 
synaptic composition are dependent on NMDAR-mediated Ca2+ influx. High 
concentrations of Tat potentiate NMDAR function following brief exposures. However, 
if and when concentrations of Tat similar to those measured in HAND patients affect 
NMDAR function was unknown. 
 First, it was determined that a pathophysiologically relevant concentration of Tat 
caused a time-dependent, biphasic change in NMDAR function. Initially, Tat potentiated 
NMDAR function via low-density lipoprotein receptor-related protein (LRP)-dependent 
activation of Src kinase. Subsequently, this potentiation adapted by gradually returning to 
basal levels via activation of the nitric oxide synthase (NOS), soluble guanylate cyclase 
(sGC), cGMP-dependent protein kinase pathway (PKG).  
 Next, effectors downstream of PKG responsible for the adaptation of the 
NMDAR function were identified. Tat activated a signaling pathway, which included the 
small GTPase RhoA and Rho-associated protein kinase (ROCK). Activation of 
RhoA/ROCK caused reorganization of the actin cytoskeleton and attenuated NMDAR 
function.  
These studies suggest that Tat potentiates NMDAR function via LRP-dependent 
activation of Src kinase and adapts following activation of a signaling cascade resulting 
from RhoA/ROCK-mediated reorganization of the actin cytoskeleton. Adaptation of 
NMDAR function following exposure to Tat has not been previously described and may 
be a neuroprotective measure to prevent excessive Ca2+ influx and neurotoxicity.  These 
studies provide molecular and temporal detail of the mechanisms that underlie Tat-
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induced NMDAR dysfunction and offer insight into potential therapeutic targets for the 
treatment of HAND. 
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I. Introduction  
Cognitive function is impaired in 30-55% of patients infected with human 
immunodeficiency virus (HIV) (Cysique et al., 2004; Tozzi et al., 2005; Heaton et al., 
2011). HIV-associated neurocognitive disorders (HAND) range in severity from a subtle 
reduction in information processing speed to significant functional impairment (Heaton et 
al., 2004). Despite effectively managing viral load with combined anti-retroviral therapy 
(cART), the prevalence of HAND remains persistently high (Heaton et al., 2010) and 
may be increasing due to prolonged patient lifespans. Currently, the efficacy of drugs to 
treat HAND is insufficient and the options are few.  
In the brain, HIV infects macrophages and microglia, but not neurons (Watkins et 
al., 1990).  Thus, HIV-induced neurotoxicity is indirect and results from the release of 
neurotoxic agents such as inflammatory cytokines, nitric oxide, glutamate, and viral 
proteins (Genis et al., 1992; Jiang et al., 2001; Kaul et al., 2001; Nath, 2002; Eugenin et 
al., 2007). The transactivator of transcription (Tat) is a protein shed from HIV-infected 
cells (Chang et al., 1997) and detected in the sera and CNS of HIV-infected patients 
(Chang et al., 1997; Hudson et al., 2000).  The level of anti-Tat antibodies in the CSF of 
HIV-infected patients without cognitive dysfunction is higher than in patients with 
HAND, suggesting antibody responses against Tat may be neuroprotective (Bachani et 
al., 2013). Despite significant improvement in the efficacy of cART for treating HIV 
infection, current regimens remain unable to halt the production of Tat (Li et al., 2009).  
Cognitive decline in patients with HAND correlates with synaptodendritic 
damage (Ellis et al., 2007). Expression of Tat in transgenic rodent models causes loss of 
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excitatory synapses resulting in learning and memory impairment (Carey et al., 2012; 
Fitting et al., 2012). In vitro, Tat-induced synapse loss (Kim et al., 2008) and neuronal 
death (Eugenin et al., 2007) are initiated by NMDAR-mediated Ca2+ influx. Tat 
potentiates NMDA-evoked increases in intracellular Ca2+ concentration ([Ca2+]i) in 
hippocampal neurons (Haughey et al., 2001).  Most studies of Tat-induced changes in 
NMDAR function are acute (min to h) while the neurotoxic effects of Tat occur over a 
prolonged time scale (h to days).  Treating primary hippocampal neurons with Tat for 24 
h causes loss of excitatory synapses (Kim et al., 2008) and simultaneous gain of 
inhibitory synapses (Hargus and Thayer, 2013) indicating that Tat evokes adaptive 
changes in the synaptic composition of neurons. Such neuroadaptations may be a 
mechanism to cope with excess excitatory input. Notably, these adaptive changes are 
prevented by pharmacologic inhibition of the NMDAR (Shin et al., 2012) indicating that 
the NMDAR is essential for synaptic neuroadaptation.  How NMDA-evoked [Ca2+]i 
responses are affected by prolonged exposure to Tat, when adaptive changes in synaptic 
composition occur, is the focus of this study. 
Here, we examined changes in NMDA-evoked increases in [Ca2+]i during 48 h 
exposure to Tat. We found that Tat evoked a biphasic change in NMDA-evoked [Ca2+]i 
responses. Tat initially potentiated the NMDA-evoked increase in [Ca2+]i via the low-
density lipoprotein receptor-related protein (LRP) and activation of Src kinase. Tat-
induced potentiation subsequently adapted by gradually returning to baseline levels. 
Adaptation resulted from activation of the nitric oxide synthase (NOS) / soluble 
guanylate cyclase (sGC) / protein kinase G (PKG) signaling pathway.  This study 
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suggests a changing role for the NMDAR during the course of HIV neurotoxicity with 
implications for treatment of HAND. 
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II. Methods 
Drugs and Reagents 
Materials were obtained from the following sources: HIV-1 Tat (Clade B, full 
length recombinant) was from the NIH AIDS Research and Reference Reagent Program 
(HIV-1 Tat protein (full length, Clade B) from John Brady and DAIDS, NIAID and from 
Prospec Tany TechnoGene Ltd. (Rehovot, Israel); recombinant rat low-density 
lipoprotein receptor-related protein associated protein 1 (RAP) was from Fitzgerald 
Industries International (Concord, MA); Dulbecco’s modified Eagle’s medium (DMEM), 
fetal bovine serum, horse serum, fura-2-acetomethyl ester (Fura-2-AM), and glycine were 
from Invitrogen (Carlsbad, CA); NMDA, NG-Nitro-L-Arginine Methyl Ester (L-
NAME), and 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were from Sigma-
Aldrich (St. Louis, MO); 4-amino-5-(4-chloro- phenyl)-7-(t-butyl)pyrazolo[3,4-
d]pyrimidine (PP2) and 4-amino-7-phenylpyrazol[3,4-d]pyrimidine (PP3), 8R,9S,11S)-(-
)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-
trizadibenzo-(a,g)-cycloocta-(c,d,e)-trinden-1-one (KT5823), and (1R*,2S*)-erythro-2-(4-
Benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol hemitartrate (ifenprodil) were from 
Tocris (Bristol, United Kingdom);  2-(2-amino-3-methyoxyphenyl)-4 H-1-benzopyran-4-
one (PD98059) was from Cell Signaling Technology (Danvers, MA); recombinant rat 
interleukin-1β was from R&D Systems (Minneapolis, MN).  
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DNA Constructs 
Dominant-negative (DN)-Fyn with the K299M mutation and DN-Src with the 
K295M mutation in pRK5 were kindly provided by Dr. Filippo Giancotti (Memorial 
Sloan Kettering Cancer Center, New York, NY); pTagRFP-N was from Evrogen 
(Moscow, Russia). The catalytically inactive mutant of full-length PKG1α containing the 
amino terminal regulatory region fused to GFP (G1αR-GFP) in pEGFP-N1 (Clontech) 
was kindly provided by Darren Browning (Georgia Regents University). The G1αR 
fragment was removed via digestion with EcoR1 and BamH1 (New England Biolabs), 
and then inserted into the multiple cloning site of DsRed2-N1 (Clontech). Mammalian 
expression vectors containing GluN1, GluN2A, and GluN2B were kindly provided by 
Stephen Traynelis (Emory University).  
 
Cell Culture 
In accordance with the University of Minnesota’s Institutional Animal Care and 
Use Committee and the NIH guide for the care and use of laboratory animals, maternal 
rats were euthanized by CO2 inhalation and fetuses were removed on embryonic day 17. 
Rat hippocampal neurons were grown in primary culture as described previously (Li et 
al., 2012). Hippocampi were dissected and placed in Ca2+- and Mg2+-free HEPES-
buffered Hanks’ salt solution (HHSS), pH 7.45. HHSS contained the following (in mM): 
HEPES 20, NaCl 137, CaCl2 1.3, MgSO4 0.4, MgCl2 0.5, KCl 5.0, KH2PO4 0.4, 
Na2HPO4 0.6, NaHCO3 3.0, and glucose 5.6. Cells were dissociated by triturating 
through a 5 mL pipette and a flame-narrowed Pasteur pipette and then re-suspended in 
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DMEM without glutamine, supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (100 U/mL and 100 mg/mL, respectively). Dissociated cells were 
then plated at a density of 60,000 to 80,000 cells/dish onto a 25-mm-round cover glass 
(#1) pre-coated with matrigel (150 µL, 0.2 mg/mL). Neurons were grown in a humidified 
atmosphere of 10% CO2 at 37°C and fed on days 1 and 7 by exchange of 75% of the 
media with DMEM supplemented with 10% horse serum and penicillin/streptomycin. 
Cells used in these experiments were cultured without mitotic inhibitors resulting in a 
mixed glial-neuronal culture consisting of 18 ± 2% neurons, 70 ± 3% astrocytes, and 9 ± 
3% microglia as indicated by immunocytochemistry (Kim et al., 2011). The cultures used 
for experimentation were grown for 12 to 15 days in vitro (DIV). 
[Ca2+]i imaging 
Intracellular Ca2+ concentration ([Ca2+]i) was recorded as previously described (Li 
et al., 2013) with minor modifications. Cells were loaded by incubation with 5 µM fura-2 
AM in 0.04% pluronic acid in HHSS for 30 min at 37°C followed by washing in the 
absence of indicator for 10 min. HIV-1 Tat and respective drugs were present during 
fura-2-AM loading, but were absent during the wash. Coverslips containing fura-2 loaded 
cells were transferred to a recording chamber, placed on the stage of an Olympus IX71 
microscope (Melville, NY), and viewed through a 20X objective. Excitation wavelength 
was selected with a galvanometer-driven monochromator (8-nm slit width) coupled to a 
75-W xenon arc lamp (Optoscan; Cairn Research). [Ca2+]i was monitored using 
sequential excitation of fura-2 at 340 and 380 nm; image pairs were collected every 1 s. 
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For experimental recordings, cells were superfused at a rate of 1-2 mL/min with HHSS 
for 1 min followed by 30 s perfusion of Mg2+-free HHSS that contained 200 µM glycine 
and either 10 or 100 µM NMDA. Fluorescence images (510/40 nm) were projected onto 
a cooled charge-coupled device camera (Cascade 512B; Roper Scientific) controlled by 
MetaFluor software (Molecular Devices). After background subtraction, the 340- and 
380-nm image pairs were converted to [Ca2+]i using the formula [Ca2+]i = Kdβ(R − 
Rmin)/(Rmax − R) (Grynkiewicz et al., 1985). The dissociation constant (Kd) for fura-2 was 
145 nM. β is the ratio of fluorescence intensity acquired with 380 nm excitation measured 
in Ca2+-free buffer (1 mM EGTA) and buffer containing saturating Ca2+ (5 mM). R is 340 
nm / 380 nm fluorescence intensity ratio.   Rmin, Rmax, and β were determined in a series 
of calibration experiments on intact cells.  Rmin and Rmax values were generated by 
applying 10 µM ionomycin in Ca2+-free buffer (1 mM EGTA) and saturating Ca2+ (5 
mM), respectively. Values for Rmin, Rmax, and β were 0.37, 9.38, and 6.46, respectively. 
These calibration constants were applied to all experimental recordings.  To generate 
pseudocolor images, a binary mask was generated by applying an intensity threshold to 
the 380 nm image and applied to [Ca2+]i images with colors assigned as indicated by the 
calibration bars in the figures. The neuronal cell body was selected as the region of 
interest for all recordings. All neurons within the imaging field were included in the 
analysis and no exclusions were made.  For time course experiments, coverslips from the 
same cell culture plating were treated in parallel and each coverslip imaged only once. 
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Transfection 
Rat hippocampal neurons were transfected between 11-12 days in vitro using a 
modification of a calcium phosphate protocol described previously (Li et al., 2012). 
Briefly, hippocampal cultures were incubated for 30 min in DMEM supplemented with 1 
mM kynurenic acid, 10 mM MgCl2, and 5 mM HEPES. A DNA/calcium phosphate 
precipitate containing 1 µg plasmid DNA per well was prepared, allowed to form for 30 
min at 21°C then added to the culture. After 90 min of incubation, cells were washed 
once with DMEM supplemented with MgCl2 and HEPES and then returned to 
conditioned media.  
Biotinylation and immunoblotting 
For biotinylation experiments, 7.5 x 106 hippocampal cells were plated in 100 x 
20 mm petri dishes.  Cells were treated with Tat alone or with an inhibitor of protein 
kinase G (KT5823) 1 h prior to the addition of Tat. Forty-eight hours later the media was 
removed and cells were washed three times with ice-cold PBS (pH 8.0) then incubated 
with 2 mM NHS-PEG4 Biotin (Thermo Fisher Scientific Inc.) in ice-cold PBS with slow 
shaking at 4 °C for 30 min protected from light. Cells processed in parallel but not treated 
with biotin served as negative controls. Biotin was gently removed and cells were washed 
four times with ice-cold PBS. Cells were collected in PBS and centrifuged at 10,000 x g 
for 1 min. Following centrifugation, supernatants were aspirated and pellets were re-
suspended in 250 µL lysis buffer consisting of PBS, 10% Triton, 20% SDS, and a 
mixture of protease inhibitors (10 µL PMSF, 100 µL Halt protease inhibitor). Samples 
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were sonicated with 3 x 1 s pulses and incubated with rocking for 30 min at 4 °C. Debris 
was pelleted in a microcentrifuge at 14,000 x g at 4 °C for 15 min and supernatants 
retained. 30 µL of sample (“Total protein”) was removed, and the rest of the sample was 
mixed by rotation for 30 min at 4 °C with 60 µL of a 50% slurry of NeutrAvidin beads 
(Thermo Fisher Scientific Inc.). Beads were washed 3 times with lysis buffer and bound 
proteins eluted in 75 µL of 2X SDS sample buffer plus 25 µL 1 M DTT by heating at 
75°C for 30 min. For immunoblotting, 3 µL 1M DTT was added to 15 µL of sample, and 
the mixture was incubated at 75°C for 10 min. Samples were then loaded onto 8% Bis-
Tris gels and run in a Tris–glycine buffer under reducing conditions. Samples were 
transferred using the iBlot transfer system (Invitrogen) onto nitrocellulose membranes 
and probed with a rabbit anti-GluN2B polyclonal antibody (1:200 dilution, Millipore). 
An IRDye 800CW donkey anti-rabbit secondary antibody (LiCor Biosciences; Lincoln, 
NE, USA) was used at a dilution of 1:1000. Visualization and quantification of band 
intensity was performed using the Odyssey Imaging System (LiCor Biosciences). 
Integrated intensity values were recorded for all lanes and normalized to the intensity of 
the untreated control.  
Statistical analysis 
For  [Ca2+]i imaging studies, an individual experiment (n=1) was defined as the 
response from a single neuron on a single coverslip. Changes in NMDA-evoked increases 
in [Ca2+]i are presented as mean ± SEM. Each experiment was replicated using at least 4 
separate coverslips from at least 2 separate cultures. For biotinylation experiments, an 
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individual experiment (n=1) was defined as the change in surface-to-total GluN2B from a 
single 100 x 20 mm petri dish. Changes in GluN2B surface expression are presented 
mean ± SEM. Each experiment was replicated using at least 10 separate petri dishes from 
10 separate cultures. Significance was determined by one-way ANOVA with Tukey’s 
post hoc test for multiple comparisons (OriginPro v8.5).  
 
III. Results 
Tat potentiates NMDA-evoked [Ca2+]i responses via LRP and a Src family kinase  
Treating primary hippocampal neurons with Tat potentiated NMDA-evoked 
increases in [Ca2+]i (Haughey et al., 2001).  We replicated this finding using fura-2-based 
digital imaging of rat hippocampal neurons in vitro. As shown in Figure 2.1, increases in 
[Ca2+]i evoked by 100 µM NMDA were potentiated following 40 min treatment with 100 
nM Tat, but not by 100 nM heat-inactivated (HI, 85°C x 30 min) Tat.   
Tat is internalized via the LRP (Liu et al., 2000) and Tat-induced neurotoxicity 
requires binding to the LRP with subsequent NMDA receptor (NMDAR)-mediated Ca2+ 
influx (Eugenin et al., 2007; Kim et al., 2008).  We sought to determine whether the LRP 
was required for Tat-induced NMDAR potentiation by using the LRP antagonist, 
receptor-associated protein (RAP). RAP binds to the LRP and prevents neuronal uptake 
of Tat (Bu, 2001).  Application of RAP (50 nM) 1 h prior to Tat application completely 
blocked Tat-induced potentiation (Fig. 2.1 G, H), suggesting that Tat potentiates 
NMDAR function via the LRP.    
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Tyrosine phosphorylation can potentiate NMDAR currents (Wang and Salter, 
1994). Tat-induced NMDAR potentiation occurs via tyrosine kinase-dependent 
phosphorylation of GluN2A and GluN2B (Haughey et al, 2001), although the specific 
tyrosine kinase involved in NMDAR potentiation remains unknown. Src family kinases 
(SFKs) enhance NMDAR function (Kohr and Seeburg, 1996), therefore we used the SFK 
inhibitor, PP2, to determine the role of SFKs in Tat-induced potentiation of NMDARs. 
Pretreatment for 1 h with PP2 (10 µM), but not its inactive analog PP3 (10 µM), 
completely blocked the Tat-induced potentiation of NMDA–evoked responses (Fig. 2.1 
G, H).  Thus, Tat-induced potentiation of NMDA-evoked increases in [Ca2+]i  requires 
the activation of a SFK. 
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Figure 2.1: HIV-1 Tat potentiates NMDA-evoked [Ca2+]i responses via LRP and a 
SFK.  [Ca2+]i  was recorded using fura-2-based digital imaging (Methods).  A, 
representative image shows fura-2 loaded neurons (scale bar = 100 µm).  B, trace shows 
change in [Ca2+]i expressed as 340 nm / 380 nm intensity ratio for the cell identified by 
the arrow in A. Cells were superfused with 100 µM NMDA (30 s) at the time indicated 
by the horizontal bar. C-F, pseudocolor images show [Ca2+]i  before  (C, E) and during 
(D, F) 30 s application of 100 µM NMDA for control (C, D) and Tat treated (100 nM x 
40 min; E, F) cells. Images were scaled as shown in B. Images were collected at times 
indicated by the letters annotating the traces in B.  G, representative traces show NMDA-
evoked [Ca2+]i increases for control ( ) cells, Tat-treated cells ( ), and cells treated 
with heat-inactivated (HI) Tat ( ).  Control ( ) and Tat-treated ( ) traces were 
from the cells indicated by the arrows in C-D and E-F, respectively.  Cells were 
pretreated for 1 h prior to Tat application with 50nM RAP, 10 µM PP2, or 10 µM PP3 as 
indicated.  H, Bar graph shows net [Ca2+]i  increase evoked by 100 µM NMDA in control 
(  ) cells, cells treated with 100 nM Tat (  ),  or 100 nM  heat-inactivated (HI) Tat (  ) 
for 40 min.  Cells were pretreated with 50nM RAP, 10 µM PP2, or 10 µM PP3 as 
indicated. ****p<0.0001 relative to respective control; ####p<0.0001 relative to Tat 
alone as determined by one-way ANOVA with 9 levels followed by Tukey’s post-test for 
multiple comparisons.  
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Tat induces a biphasic change in NMDA-evoked increases in [Ca2+]i  
 Up to 40 ng/mL of Tat has been detected in the sera of HIV-infected patients 
(Xiao et al., 2000). Previously, we have observed Tat-induced changes in synapse 
number following treatment with 50 ng/mL (3.6 nM) Tat for 24 h (Kim et al., 2008; 
Hargus and Thayer, 2013).  Thus, we hypothesized that 3.6 nM Tat would potentiate the 
NMDA-evoked increase in [Ca2+]i, but that these changes might require longer exposure 
to develop compared with 100 nM Tat.  To test this hypothesis, we recorded NMDA-
evoked [Ca2+]i responses following treatment with 50 ng/mL Tat within a 48 h window 
(Fig. 2.2).  Control and Tat-treated cultures were imaged in parallel. Exposure to Tat for 
2 h potentiated NMDA-evoked increases in [Ca2+]i. Tat-induced potentiation of the 
NMDA-evoked response peaked by 8 h then adapted, returning to baseline by 24 h and 
dropping below control by 48 h.  
Tat is susceptible to degradation by the Ca2+-activated protease, calpain-1 
(Passiatore et al., 2009). To examine the possibility that adaptation of NMDAR 
potentiation was due to the degradation of Tat, cultures received either one (0 h) or two 
(0 h, 12 h) applications of Tat (50 ng/mL). Following 16 h exposure to Tat, NMDAR 
function was potentiated in neurons treated with Tat once or twice at 39 ± 2% and 22 ± 
2% larger than control, respectively. By 24 h, amplitudes of NMDA-evoked Ca2+ influx 
from single and double Tat-treated groups returned to baseline levels and were 
comparable to control suggesting that adaptation of the NMDA-evoked response is not 
due to the degradation of Tat. Taken together, these data indicate that Tat evokes a 
biphasic change in NMDAR function.  In an attempt to determine whether enhanced Ca2+ 
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flux during the Tat-induced potentiation phase was required for subsequent adaptation, 
we blocked NMDAR-mediated Ca2+ influx with the readily reversible NMDAR 
antagonist AP5 during Tat exposure.  However, chronic NMDAR antagonism in the 
absence of Tat enhanced NMDA-evoked responses, consistent with a previous report 
showing that chronic NMDAR blockade produced a compensatory increase in the surface 
expression of NMDARs (Crump et al., 2001). Thus, we were unable to determine 
whether potentiation was necessary for adaptation.  
Application of 100 µM NMDA evoked [Ca2+]i increases in Tat-treated cells that 
peaked near saturation of the fura-2 Ca2+ indicator. A concentration-response experiment 
was conducted to determine if Tat-induced potentiation was observed when lower 
NMDA concentrations were used to probe NMDAR function. Tat-induced potentiation of 
NMDA-evoked responses was independent of NMDA concentration and was 35 ± 2%, 
14 ± 3% and 32 ± 1% larger than control for 10, 30, and 100 µM NMDA, respectively. 
Thus, to enable more accurate measurement of the [Ca2+]i  responses, we conducted the 
remaining experiments using 10 µM NMDA.  
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Figure 2.2: Tat-induces a biphasic change in NMDA-evoked [Ca2+]i responses. A, 
representative traces show NMDA-evoked [Ca2+]i (100 µM x 30 s) increases from control 
( ) neurons or neurons treated with 50 ng/mL Tat ( ) for the times indicated above the 
traces. B, plot summarizes changes in NMDA-evoked [Ca2+]i responses under control ( 
) conditions or after treatment with Tat  (  ) for 0 to 48 h. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 relative to control as determined by one-way ANOVA with 
24 levels followed by Tukey’s post-test for multiple comparisons. 
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Tat-induced potentiation of the NMDA-evoked increase in [Ca2+]i is reversible  
Tat-induced potentiation was prevented by inhibition of LRP or SFKs (Fig. 2.1).  
We next determined whether Tat-induced potentiation of NMDARs could be reversed by 
inhibition of LRP or SFKs after the potentiation was already established.  Changes in 
NMDA-evoked increases in [Ca2+]i were studied after 16, 24, 32, or 48 h exposure to Tat. 
Either RAP (50 nM) or PP2 (10 µM) was applied 1 h prior to Ca2+ imaging in the 
continued presence of Tat (50 ng/mL). Exposure to Tat for 16 h potentiated NMDA-
evoked increases in [Ca2+]i (Fig. 2.3 A, E). Potentiation was reversed by application of 
RAP or PP2 1 h prior to evoking the test response with NMDA (Fig. 2.3 A, E). 
Potentiation of NMDA-evoked responses adapted by 24 h (Fig. 2.3 B, F) and then 
dropped below control by 32 h (Fig. 2.3 C, G) and 48 h (Fig. 2.3 D, H). RAP and PP2 did 
not affect control cultures, but further reduced NMDA-evoked [Ca2+]i responses in 
cultures treated with Tat for 24 to 48 h (Fig. 2.3 B-D, F-H). These data indicate that Tat-
induced potentiation of NMDA-evoked increase in [Ca2+]i requires sustained activation of 
LRP and SFK.  Furthermore, this potentiation pathway remains activated during the 
adaptation process as indicated by the reduced amplitude of NMDA-evoked [Ca2+]i 
responses in fully-adapted cultures (24-48 h treated with Tat). 
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Figure 2.3: HIV-1 Tat-induced potentiation of NMDA-evoked increases in [Ca2+]i is 
reversible.  A-D, representative traces show NMDA-evoked [Ca2+]i increases from 
control  ( ) neurons or neurons treated with 50 ng/mL Tat ( ) for the times indicated 
above the traces. NMDA (10 µM x 30 s) was applied by superfusion at the times 
indicated by the horizontal bars. Cells were pretreated with 50 nM RAP or 10 µM PP2 1 
h prior to superfusion with 10 µM NMDA as indicated.  E-H, Bar graph shows net 
[Ca2+]i increase evoked by NMDA in control (  ) cells or cells treated with Tat  (  ).   
Cells were pretreated for 1 h with 50nM RAP or 10 µM PP2 as indicated. **p<0.01, 
****p<0.0001 relative to respective control; #p<0.05, ####p<0.0001 relative to Tat alone 
as determined by separate, one-way ANOVAs with 6 levels for each treatment time 
followed by Tukey’s post-test for multiple comparisons.  
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Src kinase mediates Tat-induced potentiation of NMDA-evoked increases in [Ca2+]i  
The SFKs, Src and Fyn, have been shown to enhance NMDAR function (Kohr 
and Seeburg, 1996). Following exposure to Tat, Src but not Fyn, associates with 
NMDARs (King et al., 2010). Due to the potential off-target effects of PP2 (Bain et al., 
2007) and the lack of drugs that are selective for Src versus Fyn, we next used a genetic 
approach to determine which SFK is responsible for potentiating the NMDA-evoked 
increase in [Ca2+]i. Primary hippocampal cultures were co-transfected with plasmids 
encoding a red-fluorescent protein (pTag-RFP-N) and dominant-negative (DN)-Fyn or 
DN-Src  (Fig. 2.4 A, B). Twenty-four hours after transfection, cells were treated with Tat 
(50 ng/mL) for 16 h, loaded with fura-2, and then imaged.  Non-expressing cells in the 
same imaging field served as controls.  Tat potentiated NMDA-evoked [Ca2+]i responses 
in non-expressing controls and cells expressing DN-Fyn (Fig. 2.4 C, D). However, 
expression of DN-Src completely blocked Tat-induced potentiation (Fig. 2.4 C, D). These 
data suggest that Tat-induced activation of Src kinase potentiates NMDA-evoked [Ca2+]i 
responses. 
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Figure 2.4: Src kinase 
mediates Tat-induced 
NMDAR potentiation. Cells 
were treated with Tat (50 
ng/mL) for 16 h as indicated. A, 
representative image shows 
neuron expressing DN-Src and 
DsRed2 in a field of fura-2 
loaded neurons (Scale bar = 25 
µm). B, pseudocolor image 
shows peak [Ca2+]i response to 
10 µM NMDA (30 s) after 16 h 
Tat treatment. Image is scaled to 
bar in C.  C, representative 
traces show NMDA-evoked 
[Ca2+]i increases for control (
) and Tat-( ) treated neurons. 
Recordings from non-expressing 
cells were from the same 
imaging field as cells expressing 
DN-Fyn or DN-Src.  D, Bar 
graph shows net [Ca2+]i  
increase evoked by 10 µM 
NMDA (30 s) in control neurons 
(  ) or neurons treated with  50 
ng/mL Tat (  ) for 16 h. 
**p<0.01 relative to  respective 
control; ####p<0.0001 relative 
to non-expressing, Tat-treated 
cells as determined by one-way 
ANOVA with 6 levels followed 
by Tukey’s post test for multiple 
comparisons. 
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Tat-induced potentiation of NMDA-evoked increases in [Ca2+]i adapts via the 
NOS/sGC/PKG pathway 
We next wanted to better understand the mechanism of adaptation following Tat-
induced NMDAR potentiation. Because adaptation of Tat-induced NMDAR potentiation 
occurred in the presence of sustained Src activation, we hypothesized that adaptation 
resulted from a sustained increase in NMDAR-mediated Ca2+ influx.  NMDAR-mediated 
Ca2+ influx following exposure to Tat leads to sustained production of nitric oxide (NO) 
(Eugenin et al., 2007).  To determine whether NO production was mediating the Tat-
induced adaptation in NMDAR function, we used a pharmacological approach.  Cultures 
were pretreated with L-NAME (100 µM), an inhibitor of nitric oxide synthase (NOS), 1 h 
prior to and during exposure to Tat for 16, 24, 32, and 48 h. L-NAME did not affect Tat-
induced NMDAR potentiation (Fig. 2.5 A, E) but did prevent adaptation of the NMDA-
evoked increase in [Ca2+]i for 48 h (Fig. 2.5 B-D, F-H). 
NO can activate soluble guanylate cyclase (sGC) resulting in the synthesis of 
cyclic guanosine monophosphate (cGMP) (Arnold et al., 1977). To determine whether 
Tat-induced NO production was mediating the adaptation of NMDA-evoked responses 
by elevating cGMP, we treated cultures with ODQ (1 µM), an inhibitor of sGC, 1 h prior 
to and during exposure to Tat for 16, 24, 32, and 48 h.  ODQ did not affect Tat-induced 
NMDAR potentiation (Fig. 2.5 A, E) but did prevent adaption of NMDA-evoked [Ca2+]i 
responses for 48 h (Fig. 2.5 B-D, F-H). 
Elevated cGMP activates cGMP-dependent protein kinase (PKG) (Kuo and 
Greengard, 1972). To determine whether Tat-induced NO production was mediating the 
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adaptation of NMDA-evoked [Ca2+]i responses by activating PKG, we treated cultures 
with the PKG inhibitor, KT5823 (10 µM), 1 h prior to and during exposure to Tat for 16, 
24, 32, and 48 h. KT5823 did not affect Tat-induced NMDAR potentiation (Fig. 2.5 A, 
E), but did prevent adaptation of NMDA-evoked increases in [Ca2+]i for 48 h (Fig. 2.5 B-
D, F-H). 
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Figure 2.5: Tat-induced potentiation of NMDAR function adapts via a 
NOS/sGC/PKG pathway.  A-D, representative traces show NMDA-evoked [Ca2+]i 
increases from control neurons ( ) or neurons treated with 50 ng/mL Tat ( ) for the 
times indicated above the traces. NMDA (10 µM x 30 s) was applied at the times 
indicated by the horizontal bars. Cells were untreated or pretreated 1 h prior to addition of 
Tat with 100 µM L-NAME, 1 µM ODQ, or 10 µM KT5823 as indicated.  E-H, Bar 
graphs show net [Ca2+]i  increase evoked by 10 µM NMDA (30 s) in control neurons ( ) 
or neurons treated with 50 ng/mL Tat ( ) for 16, 24, 32, or 48 h.*p<0.05; ****p<0.0001 
relative to  respective control; ####p<0.0001 relative to Tat alone as determined by 
separate, one-way ANOVAs with 8 levels for each treatment time followed by Tukey’s 
post-test for multiple comparisons.  
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To confirm that adaptation was mediated by PKG we complimented these 
pharmacological studies using a genetic approach.  The catalytically inactive mutant of 
PKG1α, G1αR, acts in a dominant-negative manner to inhibit PKG activity (Browning et 
al., 2001). This dominant-negative PKG construct (DN-PKG) was expressed in neurons; 
cells were then treated with Tat for 16 or 24 h, loaded with Fura-2, and then imaged. 
Exposure to Tat for 16 h potentiated the NMDA-evoked increase in [Ca2+]i in non-
expressing controls and neurons expressing DN-PKG. By 24 h, NMDA-evoked responses 
adapted in non-expressing cells, but expression of DN-PKG prevented adaptation (Fig. 
2.6). Taken together, these data suggest that adaptation of NMDA-evoked responses 
following Tat-induced potentiation occurs via a NOS/cGMP/PKG pathway.  
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Figure 2.6: PKG mediates adaptation 
of NMDAR function following Tat-
induced potentiation. A, representative 
images show neuronal expression of 
DN-PKG-DsRed2 in a field of neurons 
treated with Tat for 16 h or 24 h and 
loaded with fura-2 (scale bar = 50 µm). 
B, pseudocolor images show peak 
[Ca2+]i response to 10 µM NMDA (30 
s) following 16 h or 24 h Tat treatment. 
Images are scaled to bar in C and E. C 
and E, representative traces show 
NMDA-evoked [Ca2+]i  increases for 
control ( ) and Tat-treated ( ) cells 
following 16 h (C) or 24 h (E) exposure 
to Tat. Recordings from non-expressing 
cells were from the same imaging field 
as cells expressing DN-PKG.  D and F, 
Bar graphs show net [Ca2+]i increase 
evoked by 10 µM NMDA (30 s) in 
control neurons (  ) or neurons treated 
with 50 ng/mL Tat (  ) for 16 h (D) or 
24 h (F). *p<0.01; ***p<0.001 relative 
to  respective control; ####p<0.0001 
relative to non-expressing, Tat-treated 
cells as determined by separate, one-
way ANOVA with 4 levels for each 
treatment time followed by Tukey’s 
post test for multiple comparisons.  
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 PKG activates extracellular signal-regulated kinase (ERK) leading to the 
expression of neuroplasticity-associated proteins such as c-Fos, Egr-1, Arc, and BDNF 
(Gallo and Iadecola, 2011). Therefore, we tested the hypothesis that Tat-induced 
activation of PKG stimulates ERK signaling to affect NMDA-evoked [Ca2+]i responses. 
The MAP kinase kinase 1 (MEK1) inhibitor PD98059 (50 µM) was applied 1 h prior to 
and during treatment with Tat for 16 or 24 h. PD98059 inhibits ERK1/2 phosphorylation 
and prevents expression of the aforementioned neuroplasticity-associated proteins (Gallo 
and Iadecola, 2011). Tat-induced NMDAR potentiation was comparable in the absence 
and presence of PD98059 at 49 ± 3% and 62 ± 8% larger than control, respectively. By 
24 h, amplitudes of NMDA-evoked increases in [Ca2+]i from both treatment groups 
returned to baseline and were comparable to control, suggesting that activation of ERK 
signaling is not required for Tat-induced potentiation or adaptation of NMDARs.  
To determine if adaptation following NMDAR potentiation is unique to Tat, we 
conducted a time course experiment using interleukin-1β (IL-1β). IL-1β is a pro-
inflammatory cytokine that potentiates NMDAR-mediated currents (Liu et al., 2013) and 
NMDA-evoked  [Ca2+]i increases via activation of a SFK (Viviani et al., 2003). We 
replicated this result and found that 5 min exposure to IL-1β (50 pg/mL) potentiated 
NMDA-evoked [Ca2+]i responses. IL-1β-induced NMDAR potentiation persisted for 
longer than 24 h then NMDA-evoked  [Ca2+]i responses adapted, gradually reversing 
towards baseline by 48 h (Fig. 2.7). Pretreatment for 1 h with the soluble guanylate 
cyclase inhibitor ODQ had no effect on IL-1β-induced NMDAR potentiation and failed 
to prevent adaptation. Thus, while adaptation of potentiated NMDA-evoked Ca2+ 
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responses may be common, it appears that the mechanism of adaptation is stimulus 
specific.  
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Figure 2.7: Interleukin-1β 
(IL-1β)-induced a biphasic 
change in NMDA-evoked 
[Ca2+]i responses. A, 
representative traces show 
NMDA-evoked [Ca2+]i (10 
µM x 30 s) increases from 
control ( ) neurons or 
neurons treated with 50 
pg/mL IL-1β ( ) for the 
times indicated above the 
traces. B, plot summarizes 
the changes in NMDA-
evoked [Ca2+]i responses 
under control ( ) conditions 
or after treatment with IL-1β  
(  ) for 0 to 48 h. 
****p<0.0001 relative to 
control as determined by one-
way ANOVA with 10 levels 
followed by Tukey’s post-test 
for multiple comparisons. C, 
Cells were left untreated or 
pretreated with ODQ (1 µM) 
1 h prior to the addition of 
IL-1β as indicated. Bar 
graphs show net [Ca2+]i 
increase evoked by 10 µM 
NMDA (30 s) in control 
neurons ( ) or neurons 
treated with 50 pg/mL IL-1β  
( ) for 5 min or 48 
h.***p<0.001; ****p<0.0001 
relative to  respective control; 
####p<0.0001 relative to 
respective IL-1β x 5 min as 
determined by one-way 
ANOVA with 8 levels 
followed by Tukey’s post-test 
for multiple comparisons. 
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Tat does not affect surface expression of GluN2B   
We hypothesized that the reduction in the amplitude of NMDA-evoked [Ca2+]i 
increases following 48 h exposure to Tat was due to NMDAR internalization (Nong et 
al., 2003).  We first determined the GluN2 subtype mediating the NMDA-evoked 
response using a pharmacological approach (Fig. 2.8).   We recorded an initial NMDA 
evoked control response (response #1), allowed the cell to recover for 5 min in presence 
of ifenprodil (10 µM), a selective GluN2B antagonist (Williams, 1993), and then evoked 
a second response in the continued presence of ifenprodil (response #2). The majority (74 
± 1%) of the NMDA-evoked increase in [Ca2+]i  was mediated by ifenprodil-sensitive 
GluN2B-containing NMDARs, consistent with previous reports  indicating that GluN2B 
preferentially localizes to extrasynaptic sites (Tovar and Westbrook, 1999), including the 
neuronal cell body (She et al., 2012).  Additionally, the response amplitude in the 
presence of ifenprodil was not different in untreated control cells compared to cells 
treated with Tat for 48 h (Fig. 2.8), suggesting that the ifenprodil-insensitive component 
was not participating in the Tat-induced adaptive changes.  Thus, even though both 
GluN2A- and GluN2B-containing NMDARs are susceptible to internalization (Lavezzari 
et al., 2004), we focused on the surface expression of GluN2B subunits because the 
NMDA-evoked increase in [Ca2+]i was predominantly mediated by GluN2B-containing 
NMDARs,  the surface expression of GluN2B is more dynamic than GluN2A (Groc et 
al., 2006), and our region of interest focused on the neuronal cell body. 
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Figure 2.8: GluN2B-containing NMDARs mediate adaptation of NMDAR function. 
Forty-eight hour exposure to Tat does not affect the amplitude of NMDA-evoked [Ca2+]i  
responses in the presence of the GluN2B antagonist ifenprodil.  A, representative traces 
show NMDA-evoked [Ca2+]i increases from control  ( ) cells or neurons treated with 50 
ng/mL Tat ( ) for 48 h. NMDA (10 µM x 30 s) was applied twice by superfusion at the 
times indicated by the horizontal bars. Following recovery from an NMDA-evoked 
control response (response #1), the selective GluN2B antagonist ifenprodil (10 µM) was 
superfused for 5 min. The test response (response #2) was evoked in the sustained 
presence of ifenprodil. B, Bar graph shows net [Ca2+]i increase evoked by 10 µM NMDA 
in control (  ) cells or cells treated with Tat (  ) for 48 h in the absence (response #1) or 
presence (response #2) of the GluN2B antagonist, ifenprodil (10 µM). ****p<0.0001 
relative to control as determined by one-way ANOVA with 4 levels followed by Tukey’s 
post-test for multiple comparisons. 
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 Next, we determined whether 48 h exposure to Tat affected GluN2B surface 
expression in primary hippocampal cultures using a biotinylation approach.  To confirm 
the selectivity of our antibody for GluN2B, we first transfected HEK293 cells with 
plasmids encoding GluN1 with GluN2A or GluN2B and quantified protein expression via 
Western blot. The antibody selectively labeled GluN2B, but not GluN2A (data not 
shown).  As shown in Fig. 2.9, GluN2B surface expression was unaffected by 48 h 
exposure to Tat (50 ng/mL). Addition of KT5823 (10 µM) 1 h prior to and during 
treatment with Tat for 48 h also had no effect on GluN2B surface expression. We 
conducted a time course experiment in which cultures were treated with Tat (50 ng/mL) 
for 0, 8, 24, and 48 h. GluN2B surface expression was unaffected by Tat exposure at all 
time points (data not shown). Furthermore, treating cultures with 100 nM Tat for 1 h did 
not affect surface expression of GluN2B-containing NMDARs (data not shown). To 
confirm that the assay was sufficiently sensitive to detect changes in NMDAR surface 
expression, we induced NMDAR internalization by a 5 min pretreatment with glycine 
followed by 5 min treatment with glycine + NMDA (Nong et al., 2003). Treatment with 
glycine + NMDA evoked a 62 ± 33% decrease in GluN2B surface expression while 48 h 
treatment with Tat (50 ng/mL) tested in parallel had no effect (data not shown).  These 
data indicate that adaptation following Tat-induced NMDAR potentiation is not due to 
internalization of GluN2B.  
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Figure 2.9: Tat does not affect surface expression of GluN2B-containing NMDARs. 
A, representative Western blot showing total and surface GluN2B. B, Bar graph shows 
GluN2B surface expression, expressed as the ratio of surface-to-total GluN2B. Cultures 
were left untreated ( , n=10), treated with 50 ng/mL Tat ( , n=10) for 48 h, or treated 
with 10 µM KT5823 ( , n=11) 1 h prior to the addition of Tat for 48 h. Data are 
expressed as mean +/- SEM. One-way ANOVA with 3 conditions were performed 
followed by Tukey’s post-test for multiple comparisons.  
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IV. Discussion  
 NMDARs are implicated in many neurodegenerative disorders including HAND 
(Young et al., 1988; Kaul et al., 2001; Snyder et al., 2005; Potter et al., 2013; Rossi et al., 
2013; Spalloni et al., 2013).  The HIV-1 protein Tat is a neurotoxin involved in the 
neuropathogenesis of HIV (Nath, 2002; King et al., 2006).  Here, we used fura-2-based 
Ca2+ imaging to investigate the effects of Tat on NMDA-evoked [Ca2+]i responses in rat 
hippocampal neurons in vitro. Tat potentiated NMDA-evoked increases in [Ca2+]i by 
LRP-dependent activation of Src kinase. Intriguingly, NMDA-evoked responses adapted 
following Tat-induced potentiation by activation of the NOS/sGC/PKG pathway. 
Adaptation of NMDA-evoked responses may be a novel neuroprotective mechanism to 
prevent excessive Ca2+ influx through NMDARs and could identify new targets for the 
treatment of HAND.  The signaling pathways responsible for the biphasic modulation of 
NMDARs during exposure to Tat are summarized in Figure 2.10. 
 Tat has been detected in the brains of patients with HIV (Wiley et al., 1996; Del 
Valle et al., 2000; Hudson et al., 2000). Tat is shed by HIV-infected cells (Steinaa et al., 
1994; Chang et al., 1997) and can affect NMDAR function directly and indirectly. 
Previous work showed that Tat directly activates the NMDAR (Song et al., 2003) 
resulting in neurotoxicity (Li et al., 2008). Other reports indicate that Tat indirectly 
enhances NMDAR function via binding to and relieving the inhibitory effect of Zn2+ 
(Chandra et al., 2005) or via tyrosine kinase-mediated phosphorylation of NMDARs 
(Haughey et al., 2001). We found that Tat indirectly potentiated NMDA-evoked increases 
in [Ca2+]i as indicated by prevention of potentiation by the LRP antagonist, RAP. Tat also 
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induces synapse loss (Kim et al., 2008; Shin et al., 2012) and cell death (Eugenin et al., 
2007) via an LRP-dependent mechanism (Liu et al., 2000). LRP1 recognizes over 30 
ligands with high affinity (Herz and Strickland, 2001).  Some of these agents alter 
NMDAR function.  For example, activated α2-macroglobulin (Qiu et al., 2002) and 
amyloid-β (Snyder et al., 2005) inhibit NMDA-evoked currents and ApoE4 potentiates 
NMDAR function (Qiu et al., 2003). We used a combined pharmacological and genetic 
approach to show that the previously described potentiation of NMDA-evoked [Ca2+]i 
responses by Tat (Haughey et al., 2001) was mediated by LRP-dependent activation of 
Src. The mechanism by which Tat activates Src following binding to LRP is unclear. 
Ligand binding to LRP activates SFKs (Bock and Herz, 2003); (Shi et al., 2009). Neurons 
from animals with an inactivating knock-in mutation in the Lrp1 gene exhibit reduced 
phosphorylation of GluN2B tyrosine-1472, although this particular mutation increased 
both LRP1 and GluN2B surface expression (Maier et al., 2013). Thus, it’s possible that 
Tat binding to the LRP activates a signaling cascade resulting in phosphorylation of 
NMDARs.  Alternatively, following internalization, Tat causes fundamental changes in 
endolysosomal structure and function (Hui et al., 2012); thus, it’s possible that Tat 
disrupts endolysosomal membrane integrity and escapes the endosome to activate Src.  
NMDAR function could be directly affected by Src-mediated phosphorylation (Salter and 
Kalia, 2004) or indirectly via activation of other Src substrates.  
Tat-induced potentiation of the NMDA-evoked increase in [Ca2+]i followed a 
biphasic time course.  The Tat-induced NMDAR potentiation peaked at 8 h and then 
NMDA-evoked responses returned to baseline by 24 h eventually dropping below control 
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by 48 h.  Down-regulation of NMDAR function over the course of hours to days has been 
described previously following ethanol exposure (Wu et al., 2011) and for excitatory 
conditions such as benzodiazepine withdrawal (Shen and Tietz, 2011). Adaptation 
following Tat-induced NMDAR potentiation has not been previously described, although 
it does correlate with adaptive changes in synapse number induced by Tat.  Twenty-four 
hour exposure to 50 ng/ml Tat produced a 50 ± 7% loss of glutamatergic synapses and a 
simultaneous 38 ± 3% increase in GABAergic synapses (Kim et al., 2008; Hargus and 
Thayer, 2013). We suggest that Tat-induced synaptic changes and attenuation of NMDA-
evoked [Ca2+]i responses are part of a neuroprotective response orchestrated by the cell to 
reduce excess excitatory input.  
Adaptation of NMDA-evoked [Ca2+]i responses resulted from the activation of a 
NOS/sGC/PKG signaling pathway.  A series of pharmacological and genetically-
expressed inhibitors of this pathway prevented adaptation without affecting potentiation 
of NMDARs or NMDA-evoked responses in cells that were not exposed to Tat. PKG-
mediated phosphorylation of the vasodilator-stimulated phosphoprotein (VASP), a 
protein expressed in neurons and used to assess PKG activity (Butt et al., 1994; Wang 
and Robinson, 1997), increased following 24 h exposure to Tat (Shin & Thayer 2014) 
providing further support for Tat-induced activation of an NO-PKG pathway.   Thus, this 
pathway was only activated after exposure to Tat, possibly resulting from potentiation. 
Sustained Tat-induced NO production results following the formation of a 
macromolecular complex composed of LRP, PSD95, NMDAR, and nNOS (Eugenin et 
al., 2007). NO inhibits NMDA receptor function (Manzoni et al., 1992), although this 
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feedback inhibition is generally thought to result from the direct nitrosylation of 
NMDARs (Lei et al., 1992; Lipton and Stamler, 1994) rather than activation of PKG. 
Activation of PKG leads to suppression of NMDAR-mediated currents (Furukawa and 
Mattson, 1998), however the mechanism by which PKG attenuates NMDAR function is 
unclear. 
  Adaptation of potentiated NMDA-evoked [Ca2+]i increases is not unique to Tat. 
Prolonged exposure to IL-1β also resulted in potentiated followed by attenuated 
responses to NMDA, although it appears that the mechanism of adaptation is stimulus 
specific. Adaptation of Tat-induced NMDAR potentiation does not appear to result from 
attenuation of Src activity.  The SFK inhibitor, PP2, suppressed NMDA-evoked increases 
in [Ca2+]i below control in fully-adapted, Tat-treated cells, although it had no effect on 
NMDA-evoked responses in naive cells, suggesting that Src remained active even in cells 
in which NMDA-evoked responses had returned to control levels.  Sustained Src-
mediated phosphorylation of Tyr 1472 on the C-terminal tail of GluN2B could disrupt 
AP-2 binding and prevent clathrin-mediated endocytosis (Lavezzari et al., 2003), which 
might explain the sustained NMDAR surface expression indicated by the biotinylation 
experiments. Biotinylation experiments indicated that adaptation was not due to 
internalization of GluN2B-containing NMDARs. Thus, an additional process was 
activated to counteract the sustained Src-mediated potentiation of the NMDA-evoked 
increase in [Ca2+]i.  One possibility that could account for the reduction in NMDA-
evoked responses without a concomitant decrease in GluN2B surface expression is Ca2+-
induced cytoskeletal changes. Depolymerization of actin protects from excitotoxicity by 
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reducing glutamate receptor-mediated Ca2+ influx (Furukawa et al., 1995). PKG is known 
to alter actin polymerization via Rho-associated kinase (Sunico et al., 2010) and such 
cytoskeletal changes reduce Ca2+ influx through the NMDAR (Rosenmund and 
Westbrook, 1993; Lei et al., 2001).  Perhaps prolonged exposure to Tat alters the gating 
or ligand binding properties of the NMDAR by affecting the physical interaction between 
the actin cytoskeleton and NMDARs resulting in attenuated NMDA-evoked responses. 
The biphasic change in NMDA-evoked [Ca2+]i responses induced by Tat raises 
interesting questions about the balance between optimal NMDAR function and neuronal 
survival. Pharmacologic inhibition of NMDARs protects neurons from Tat-induced cell 
death (Shin et al., 2012); thus, the adaptation described here would seem likely to 
improve neuronal survival.  However, Tat-induced cell death and NMDAR adaptation are 
both prevented by inhibition of NOS with L-NAME (Eugenin et al., 2007).  Does the 
timing, duration, and amount of NO production distinguish protective from toxic effects? 
Intriguingly, NO can be neuroprotective or neurotoxic (Lipton et al., 1993). NO confers 
neuroprotection by several mechanisms. It directly attenuates NMDAR-mediated Ca2+ 
influx via s-nitrosylation resulting in improved neuronal survival (Choi et al., 2000; 
Jaffrey et al., 2001). Furthermore, NO can stimulate the sGC/cGMP/PKG pathway to 
produce neuroprotective proteins such as the transcription factor CREB and the kinase 
Akt (Contestabile and Ciani, 2004). Alternatively, the neuroprotective effects of NO may 
be overwhelmed by nitrosative stress following prolonged, persistent, and excessive 
production of NO, ultimately resulting in neurotoxicity and cell death.  
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Although NO production is necessary for Tat-induced cell death to occur 
(Eugenin et al., 2007), impaired brain function from HIV initially results from 
synaptodendritic injury that precedes overt neuronal death. Proper NMDAR function is 
essential for normal cognition. For example, overexpression of GluN2B-containing 
NMDARs enhances learning and memory function (Tang et al., 1999) while inhibition of 
NMDARs impairs these processes (Malhotra et al., 1996; Newcomer and Krystal, 2001). 
Does the cognitive decline observed in patients with HAND result, in part, from 
excessive attenuation of NMDAR function?  If so, then the pathways that potentiate and 
attenuate NMDARs during a neurotoxic challenge may prove useful targets for the 
pharmacological treatment of HAND.  Additionally, if the complex time course of 
NMDAR modulation observed during in vitro exposure to Tat is extrapolated to HAND, 
then different therapeutic approaches may be required for different stages of the disease.  
In summary, we have shown that exposure to Tat evokes a biphasic modulation of 
NMDA-evoked [Ca2+]i responses.  An LRP/Src pathway initially potentiates NMDA-
evoked increases in [Ca2+]i and then activation of the NOS/sGC/PKG signaling pathway 
attenuates NMDA-evoked responses.  Future experiments to determine how these 
pathways balance NMDAR-dependent cognitive functions with NMDAR-dependent 
toxicity in vivo may inform the targeting and timing of neuroprotective agents of 
potential use in treating HAND. 
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Figure 2.10: Proposed mechanism of Tat-induced NMDAR potentiation and 
adaptation. Tat interacts with LRP leading to the activation Src-kinase. Src kinase 
potentiates NMDA-evoked [Ca2+]i responses. Increased Ca2+ flux activates NOS to 
produce NO. NO binds to sGC stimulating the synthesis of cGMP. cGMP then activates 
PKG leading to the reduction of NMDA-evoked [Ca2+]I responses. Solid and dashed 
arrows represent direct and potentially indirect connections, respectively. 
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I. Introduction  
 Approximately half of HIV-infected patients in the U.S. are affected by HIV-
associated neurocognitive disorders (HAND) (Cysique et al., 2004; Tozzi et al., 2005; 
Heaton et al., 2011) and the prevalence is likely higher in areas of the world where 
effective pharmacotherapy is uncommon. HAND ranges in severity from asymptomatic 
to severely debilitating (Heaton et al., 2004; Antinori et al., 2007). Multiple reports 
during the past decade indicate that cognitive dysfunction remains a significant and 
persistent problem despite effective management of viral load with combination anti-
retroviral therapy (cART) (Antinori et al., 2007; Heaton et al., 2010; Heaton et al., 2011). 
Current cART regimens prolong the lifespan of patients by effectively managing viral 
load. Unfortunately, HAND remains common among HIV-infected patients (Heaton et 
al., 2010) and the therapeutic approaches to combat HIV-associated cognitive impairment 
remain ineffective (Uthman and Abdulmalik, 2008). 
Penetrance of HIV into the CNS occurs as early as 2 weeks post infection 
(Resnick et al., 1988; Davis et al., 1992; An et al., 1999). Once inside the CNS, HIV 
infects microglial cells and perivascular macrophages (Albright et al., 1999; Williams et 
al., 2001), which serve as reservoirs for viral replication. HAND is thought to arise, in 
part, from latent viral reservoirs that are not entirely accessible to cART. Because HIV 
does not infect neurons, neuronal injury leading to cognitive impairment results from 
indirect mechanisms. Namely, HIV-infected cells within the CNS release agents that are 
neurotoxic including inflammatory cytokines (Genis et al., 1992), nitric oxide (Eugenin et 
al., 2007), and glutamate (Jiang et al., 2001), as well as the viral proteins, gp120 
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(Schneider et al., 1986) and the transactivator of transcription (Tat) (Chang et al., 1997).  
While, HIV-induced neuropathogenesis likely involves a combination of these agents to 
create a neurotoxic environment, Tat is particularly important because current 
antiretroviral therapy is unable to halt the production of this potent neurotoxin once 
integrated into cellular DNA (Li et al., 2009). 
Tat is a non-structural viral protein that is responsible for initiating transcription 
of the HIV genome (Sodroski et al., 1985a; Sodroski et al., 1985b). In addition to its role 
as a transcriptional transactivator, Tat is shed from HIV-infected cells (Chang et al., 
1997) and is detected in the CNS and sera of HIV-infected patients (Del Valle et al., 
2000; Hudson et al., 2000). Anti-Tat antibody titers in the cerebrospinal fluid of HIV+ 
patients are approximately 30% lower in cognitively impaired patients relative to 
unimpaired patients, suggesting that antibody responses against Tat may be 
neuroprotective and preserve cognitive function (Bachani et al., 2013).  Cognitive decline 
in HAND correlates with damage to synaptodendritic structures, including axonal 
disruptions and pruning of dendritic spines (Ellis et al., 2007). In a transgenic mouse 
model, induction of Tat expression results in a loss of dendritic spines resulting in 
learning and memory impairment (Fitting et al., 2010; Carey et al., 2012; Fitting et al., 
2013). Similarly, exposure of primary hippocampal neurons to Tat in vitro causes loss of 
excitatory synapses (Kim et al., 2008), gain of inhibitory synapses (Hargus and Thayer, 
2013), and causes loss of presynaptic terminals (Shin and Thayer, 2013). Importantly, 
almost all instances of Tat-induced neurotoxicity are prevented by pharmacologic 
inhibition of the NMDA receptor (NMDAR) (Eugenin et al., 2007; Kim et al., 2008; Shin 
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et al., 2012; Hargus and Thayer, 2013) indicating that Tat-induced neurotoxicity requires 
NMDAR-mediated Ca2+ influx.  
Tat potentiates NMDA-evoked responses (Haughey et al., 2001; Chandra et al., 
2005) which then adapt by gradually returning to and eventually dropping below basal 
responses (Krogh et al., 2014). Reduction of NMDAR function and a decrease in the ratio 
of excitatory-to-inhibitory synapses may be neuroprotective responses orchestrated by the 
cell to prevent excessive Ca2+ influx and excitotoxicity. Thus, these adaptive changes 
may improve neuronal survival at the cost of impaired network function. The signaling 
pathway responsible for adaptation of NMDA-evoked [Ca2+]i responses following 
prolonged exposure to Tat is therefore the focus of this study. 
Here we examined NMDAR function during 24 h exposure to Tat. Previously, we 
found that Tat evoked a biphasic change in NMDAR function (Krogh et al., 2014). As 
illustrated in figure 3.1, Tat potentiated NMDA-evoked increases in intracellular Ca2+ 
concentration ([Ca2+]i) via the low-density lipoprotein receptor-related protein (LRP) and 
activation of Src tyrosine kinase. Subsequently, NMDA-evoked responses adapted by 
gradually returning to basal levels after 24 h exposure to Tat and eventually dropping 
below baseline responses by 48 h. Adaptation resulted from activation of a nitric oxide 
synthase (NOS), soluble guanylate cyclase (sGC), cGMP-dependent protein kinase 
(PKG) signaling pathway (Krogh et al., 2014). However, effectors downstream of PKG 
responsible for attenuating the NMDA-evoked response have not been identified. Here 
we show that Tat activates a signaling pathway that includes the small GTPase RhoA and 
Rho-associated protein kinase (ROCK). Activation of RhoA/ROCK results in 
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reorganization of the actin cytoskeleton leading to attenuated NMDA-evoked increases in 
[Ca2+]i. Abnormal activation of RhoA/ROCK has been observed in various models of 
CNS disorders including Alzheimer’s disease, stroke, and multiple sclerosis. Thus, 
RhoA/ROCK are promising drug targets for the treatment of various neurological 
conditions; however, little is known about this signaling pathway in HAND. This study 
suggests that following Tat-induced potentiation, NMDA-evoked responses are reduced 
following RhoA/ROCK-mediated reorganization of the actin cytoskeleton.  
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Figure 3.1: HIV-1 Tat causes a biphasic change in NMDA-evoked increases in 
[Ca2+]i 
a, Stylized traces ( ) depict time-dependent, biphasic changes in NMDA-evoked 
increases [Ca2+]i following exposure to HIV-1 Tat for the time indicated above the trace. 
The previously reported (Krogh et al., 2014) sequence of events listed below the traces 
indicates that Tat-induced activation of an LRP/Src kinase pathway resulted in NMDAR 
potentiation. Subsequently, NMDARs adapted following activation of the 
NOS/sGC/PKG signaling pathway. Identifying downstream effector(s) of PKG is the 
goal of this study. b, Representative pseudocolor images (scale bar = 100 µm) show peak 
response to NMDA (10µM, 30 s) in primary hippocampal neurons treated with Tat for 
the time indicated in the image panel. Images were scaled from 0 to 700 nM as indicated 
by the color bar on the y-axis.  
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II. Materials and Experimental Methods 
Drugs and Reagents 
Materials were obtained from the following sources: HIV-1 Tat (Clade B, 1-86 
amino acids) was acquired from the NIH AIDS Research and Reference Reagent 
Program (HIV-1 Tat protein from Dr. John Brady and DAIDS, NIAID) and from Prospec 
Tany TechnoGene Ltd. (Rehovot, Israel); Dulbecco’s modified Eagle’s medium 
(DMEM), fetal bovine serum, horse serum, fura-2-acetomethyl ester (Fura-2-AM), and 
glycine were obtained from Invitrogen (Carlsbad, CA). Phalloidin-Oleate, Y27632 
(Trans-4-[(1R)-1-Aminoethyl]-N-4pyridinylcyclohexanecarboxamide dihydrochloride), 
and Cytochalasin D (zygosporium mansonii) were acquired from EMD Millipore 
(Billerica, MA); Rho Inhibitor I (exoenzyme C3 transferase) was obtained from 
Cytoskeleton, Inc. (Denver, CO); H1152 ((S)-(+)-2-Methyl-1-[(4-methyl-5-
isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride), latrunculin A (4-
[(1R,4Z,8E,10Z,12S,15R,17R)-17-Hydroxy-5,12-dimethyl-3-oxo-2,16-
dioxabicyclo[13.3.1]nonadeca-4,8,10-trien-17-yl)-2-thiazolidinone), and jasplakinolide 
(Cyclo[(3R)-3-(4-hydroxyphenyl)-β-alanyl-(2S,4E,6R,8S)-8-hydroxy-2,4,6-trimethyl-4-
nonenoyl-L-alanyl-2-bromo-N-methyl-D-tryptophyl]) were acquired from Tocris (Bristol, 
UK); ML-7 (1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine 
hydrochloride) and NMDA were obtained from Sigma-Aldrich (St. Louis, MO). 
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DNA Constructs 
 Dominant Negative (DN)-RhoA (plasmid 15901) and constitutively active (CA)-
RhoA (plasmid 15900) were obtained from Addgene (Cambridge, MA). pTagRFP-N was 
acquired from Evrogen (Moscow, Russia). pEGFP-Actin was obtained from Clontech 
(Mountain View, CA). 
 
Cell Culture 
In accordance with the University of Minnesota’s Institutional Animal Care and 
Use Committee and the NIH guide for the care and use of laboratory animals, maternal 
rats were euthanized by CO2 inhalation and fetuses were removed on embryonic day 17. 
Rat hippocampal neurons were grown in primary culture as described previously 
(Waataja et al. 2008). Hippocampi were dissected and placed in Ca2+- and Mg2+-free 
HEPES-buffered Hanks’ salt solution (HHSS), pH 7.45. HHSS contained the following 
(in mM): HEPES 20, NaCl 137, CaCl2 1.3, MgSO4 0.4, MgCl2 0.5, KCl 5.0, KH2PO4 
0.4, Na2HPO4 0.6, NaHCO3 3.0, and glucose 5.6. Cells were dissociated by triturating 
through a 5 mL pipette and a flame-narrowed Pasteur pipette and then re-suspended in 
DMEM without glutamine, supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (100 U/mL and 100 mg/mL, respectively). Dissociated cells were 
then plated at a density of 50,000 to 60,000 cells/dish onto a 25-mm-round cover glass 
(#1) pre-coated with matrigel (150 µL, 0.2 mg/mL). Neurons were grown in a humidified 
atmosphere of 10% CO2 (pH 7.4) at 37°C, and fed on days 1 and 7 by exchange of 75% 
of the media with DMEM supplemented with 10% horse serum and 
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penicillin/streptomycin. Cells used in these experiments were cultured without mitotic 
inhibitors resulting in a mixed glial-neuronal culture consisting of 18 ± 2% neurons, 70 ± 
3% astrocytes, and 9 ± 3% microglia as indicated by immunocytochemistry (Kim et al. 
2011). The cultures used for experiments were 12 to 15 days in vitro (DIV). 
[Ca2+]i imaging 
Intracellular Ca2+ concentration ([Ca2+]i) was recorded as previously described (Li 
et al., 2013) with minor modifications. Cells were loaded with indicator by incubation 
with 5 µM fura-2 AM in 0.04% pluronic acid in HHSS for 30 min at 37°C followed by 
washing in the absence of indicator for 10 min. HIV-1 Tat and respective drugs were 
present during fura-2-AM loading, but were absent during the wash. Coverslips 
containing fura-2-AM loaded cells were transferred to a recording chamber, placed on the 
stage of an Olympus IX71 microscope (Melville, NY), and viewed through a 20X 
objective. Excitation wavelength was selected with a galvanometer-driven 
monochromator (8-nm slit width) coupled to a 75-W xenon arc lamp (Optoscan; Cairn 
Research). [Ca2+]i was monitored using sequential excitation of fura-2 at 340 and 380 nm; 
image pairs were collected every 1 s. For experimental recordings, cells were superfused 
at a rate of 1-2 mL/min with HHSS for 1 min followed by 30 s perfusion of Mg2+-Free 
HHSS that contained 200 µM glycine and 10 µM NMDA. Fluorescence images (510/40 
nm) were projected onto a cooled charge-coupled device camera (Cascade 512B; Roper 
Scientific) controlled by MetaFluor software (Molecular Devices). After background 
subtraction, the 340- and 380-nm image pairs were converted to [Ca2+]i using the formula 
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[Ca2+]i = Kdβ(R − Rmin)/(Rmax − R) (Grynkiewicz et al. 1985).  The dissociation constant 
(Kd) for fura-2 is 145 nM and R is the 340 nm / 380 nm fluorescence intensity ratio.  
Rmin, Rmax, and β were determined in a series of calibration experiments on intact cells.  
Rmin and Rmax values were generated by applying 10 µM ionomycin in Ca2+-free HHSS 
supplemented with 1 mM EGTA and saturating (5 mM) Ca2+, respectively. β is the ratio 
of fluorescence intensity acquired with 380 nm excitation measured in Ca2+-free buffer 
and buffer containing saturating (5 mM) Ca2+.  Values for Rmin, Rmax, and β were 0.37, 
9.38, and 6.46, respectively. These calibration constants were applied to all experimental 
recordings. For time course experiments, coverslips from the same cell culture plating 
were treated in parallel and each coverslip imaged only once. To generate pseudocolor 
images, a binary mask was created by applying an intensity threshold to the 380 nm 
image and then applied to [Ca2+]i images with colors assigned as indicated by the 
calibration bars in the figures (Fig. 3.1 b). The neuronal cell body was selected as the 
region of interest for all recordings. All neuronal cells types within imaging fields were 
included in the analysis and no exclusions were made. 
 
Transfection 
Rat hippocampal neurons were transfected between 11-12 days in vitro using a 
modification of a calcium phosphate protocol described previously (Li et al., 2012). 
Briefly, hippocampal cultures were incubated for 30 min in DMEM supplemented with 1 
mM kynurenic acid, 10 mM MgCl2, and 5 mM HEPES. A DNA/calcium phosphate 
precipitate containing 1 µg plasmid DNA per well was prepared, allowed to form for 30 
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min at 21°C then added to the culture. Following a 90 min incubation, cells were washed 
once with DMEM supplemented with MgCl2 and HEPES and then returned to 
conditioned media.  
Confocal microscopy of EGFP-Actin 
Glass-bottom petri dishes containing neurons transfected with EGFP-Actin and 
Tag-RFP were sealed with Parafilm, transferred to the stage of an inverted confocal 
microscope (Olympus Fluoview 300, Melville, NY) and viewed through a 60X oil-
immersion objective (NA=1.4). EGFP-Actin was excited at 488 nm with an argon ion 
laser and emission collected at 530 nm (10 nm band pass). Tag-RFP was excited at 543 
nm with a green HeNe laser and emission collected at >605 nm. 1 µm optical sections 
spanning 8 µm in the z-dimension were collected and these optical sections were 
combined through the z-axis into a compressed z-stack. To enable repeated imaging of 
the same cell, the location of the cell was recorded using micrometers attached to the 
stage of the microscope. The cell culture dish was returned to the CO2 incubator between 
image collections. Images were processed using MetaMorph 7.7 image processing 
software. Compressed z-stacks were created from the Tag-RFP and EGFP-Actin image 
stacks and then overlaid. 
 
Statistical analysis 
For [Ca2+]i imaging studies, an individual experiment (n=1) was defined as the 
change in NMDA-evoked [Ca2+]i response from a single neuron on a single coverslip. 
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Changes in NMDA-evoked [Ca2+]i are presented as mean ± SEM. Each experiment was 
replicated using at least 4 separate coverslips from at least 2 separate cultures.  
Significant differences were determined by one-way ANOVA with Tukey’s post hoc test 
for multiple comparisons (OriginPro v8.5).  
 
III. Results 
 
HIV Tat-induced potentiation of NMDAR function adapts via activation of RhoA 
Our previous study showed that treating rat hippocampal neurons in culture with the 
HIV Tat protein initially potentiated NMDA-evoked Ca2+ responses, which then adapted 
back to baseline during continued exposure to Tat (Krogh et al., 2014). Adaptation of 
NMDAR function occurred after activation of a NOS/sGC/PKG signaling cascade, 
however effectors downstream of PKG had not yet been identified (Fig. 3.1). Because 
cytoskeletal changes regulate NMDAR function (Rosenmund and Westbrook, 1993; 
Furukawa et al., 1995) and RhoA is a downstream effector of PKG (Sauzeau et al., 2003; 
Rolli-Derkinderen et al., 2005; Sunico et al., 2010) that affects the actin cytoskeleton, we 
examined the possibility that adaptation of NMDARs required RhoA. We hypothesized 
that RhoA activation was necessary for the reduction in NMDA-evoked [Ca2+]i responses 
after Tat-induced potentiation. To test this hypothesis, we used pharmacological and 
genetic approaches. NMDAR function was assessed in rat hippocampal neurons (DIV12-
15) using fura-2-based digital imaging to record [Ca2+]i increases evoked by superfusing 
NMDA (10 µM) and glycine (200 µM) in Mg2+-free HHSS onto the cells for 30 s. 
Cultures were pretreated with a cell-permeable inhibitor of RhoA, exoenzyme C3 
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transferase (ExoC3, 2.5 µg/mL), 1 h prior to and during exposure to Tat for 16 or 24 h. 
ExoC3 did not affect Tat-induced NMDAR potentiation, but did prevent adaptation of the 
NMDA-evoked increase in [Ca2+]i by 24 h (Fig. 3.2 a, b).  
Next, we wanted to confirm the role of RhoA in reducing NMDA-evoked [Ca2+]i 
responses by co-expressing plasmids encoding either dominant negative (DN)-RhoA 
(T19N) or constitutively active (CA)-RhoA (Q63L) with a red-fluorescent protein (RFP) 
and imaging these cells in parallel. Neurons expressing the constructs of interest were 
compared to non-expressing neurons in the same imaging field for an internal 
comparison.  Cells were treated with Tat for 16 or 24 h, loaded with fura-2, and then 
imaged (Fig. 3.2 c, d). In non-expressing control (untreated) cells, NMDA-evoked [Ca2+]i 
responses were similar to responses in neurons expressing DN-RhoA. However, 
expression of CA-RhoA inhibited NMDA-evoked responses by approximately 50%. 
Exposure to Tat for 16 h potentiated NMDAR function in non-expressing cells and in 
neurons expressing DN-RhoA. However, cells expressing CA-RhoA were markedly 
inhibited relative to non-expressing and DN-RhoA-expressing neurons with the same 
treatment time. After 24 h exposure to Tat, NMDAR function adapted in non-expressing 
cells, but cells expressing DN-RhoA remained potentiated. Neurons expressing DN-
RhoA (Fig. 3.2 f) were morphologically distinct and exhibited increased dendritic 
branching relative to neurons expressing RFP only (Fig. 3.2 e), while expression of CA-
RhoA (Fig. 3.2 g) caused dendritic simplification consistent with previous reports (Da 
Silva et al. 2003, Chen & Firestein 2007).  These data indicate that adaptation of 
NMDAR function following Tat-induced potentiation requires activation RhoA.  
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Figure 3.2: Adaptation of NMDAR function after Tat-induced potentiation requires 
RhoA   
a, Representative traces show NMDA-evoked [Ca2+]i increases from control  ( ) 
neurons or neurons treated with 50 ng/mLTat ( ) for 16 h or 24 h. Cells were pretreated 
with 2.5 µg/mL Exoenzyme C3 Transferase (ExoC3) 1 h prior to the addition of Tat. 
NMDA (10 µM, 30 s) was applied by superfusion at the times indicated by the horizontal 
bars. b, Bar graph shows net [Ca2+]i increase evoked by 10 µM NMDA in control (  ) 
cells or cells treated with Tat (  ) for 16 h or 24 h. *p<0.05; ***p<0.001; ****p<0.0001 
relative to respective control; ####p<0.0001 relative to 24 h Tat-treated neurons as 
determined by separate, one-way ANOVAs with 4 levels per treatment time followed by 
Tukey’s post-test for multiple comparisons. c, representative traces show NMDA-evoked 
[Ca2+]i increases from non-expressing  ( ) neurons or neurons expressing DN-RhoA (
) or  CA-RhoA  ( ) that were left untreated (control) or treated with Tat for 16 h or 
24 h. d, Bar graph shows net [Ca2+]i increase evoked by 10 µM NMDA in non-expressing 
( ) neurons or neurons expressing DN-RhoA ( ) or CA-RhoA ( ). Neurons were left 
untreated (control) or treated with Tat for 16 h or 24 h as indicated. Representative 
images of neurons expressing RFP only (e) or RFP and DN-RhoA (f) or CA-RhoA (g) 
(scale bar = 50 µm). Images were inverted to enhance contrast between the neuron and 
background. *p<0.05; **p<0.01; ***p<0.001  relative to non-expressing neurons within 
respective treatment group as determined by separate, one-way ANOVAs with 3 levels 
per treatment time followed by Tukey’s post-test for multiple comparisons.  
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Tat-induced potentiation of NMDAR function adapts via activation of ROCK 
The principal downstream effector of RhoA is ROCK (Matsui et al., 1996) and 
activation of ROCK results in rundown of NMDA-evoked currents via an actin-
dependent mechanism (Beazely et al., 2008). Therefore, we hypothesized that ROCK 
activation was necessary for adaptation of NMDAR function after Tat-induced 
potentiation. To test this hypothesis, cultures were pretreated with an inhibitor of ROCK 
1 h prior to and during Tat treatment for 16 or 24 h (Fig. 3.3). Inhibition of ROCK with 
Y27632 (10 µM) or H1152 (10 µM) did not affect Tat-induced NMDAR potentiation 
after 16 h treatment. However, the ROCK inhibitors prevented adaptation of NMDA-
evoked [Ca2+]i after exposure to Tat for 24 h. These data suggest that adaptation of 
NMDAR function following Tat-induced potentiation requires activation ROCK. 
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Figure 3.3: Adaptation of NMDAR function after Tat-induced potentiation requires 
ROCK 
a, Representative traces show NMDA-evoked [Ca2+]i increases from control  ( ) 
neurons or neurons treated with 50 ng/mLTat ( ) for 16 h or 24 h. Cells were pretreated 
with 10 µM Y27632 or 10µM H1152 for 1 h prior to the addition of Tat. NMDA (10 µM, 
30 s) was applied by superfusion at the times indicated by the horizontal bars. b, Bar 
graph shows net [Ca2+]i increase evoked by 10 µM NMDA in control (  ) cells or 
neurons treated with Tat (  ) for 16 h or 24 h. **p<0.01, ****p<0.0001 relative to 
respective control; ####p<0.0001 relative to 24 h Tat-treated neurons as determined by 
separate, one-way ANOVAs with 6 levels per treatment time followed by Tukey’s post-
test for multiple comparisons.  
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Actin reorganization reduces NMDAR function 
RhoA/ROCK signaling activates several targets that affect the actin cytoskeleton 
including LIM-kinase and cofilin (Maekawa et al., 1999), profilin (Da Silva et al., 2003), 
as well as myosin light chain phosphatase and myosin light chain kinase (MLCK) 
(Totsukawa et al., 2000). MLCK regulates NMDAR activity by increasing actomyosin 
contractility (Lei et al., 2001), thus we hypothesized that MLCK activation is necessary 
for the reduction in NMDA-evoked responses after Tat-induced potentiation. To test this 
hypothesis, cultures were pretreated with an inhibitor of MLCK, ML-7 (10 µM), for 1 h 
prior to and during Tat treatment for 16 or 24 h.  ML-7 did not affect Tat-induced 
NMDAR potentiation by 16 h and, unexpectedly, did not block adaptation of NMDAR 
function by 24 h (Fig 3.4. a, b). Consistent with previous reports (Lei et al., 2001), ML-7 
inhibited NMDA-evoked responses by approximately 40% and 25% following 16 h and 
24 h treatment, respectively. Additionally, neurons exposed to ML-7 had vacuole-like 
structures present within the neuronal cell body similar to previous reports (Sulzer et al., 
2008). These data do not support the hypothesized role for MLCK and suggest that 
adaptation of NMDAR function occurs via another effector downstream from ROCK.  
We next examined the role of the actin cytoskeleton in Tat induced regulation of 
NMDAR function.  Cultures were pretreated with cytochalasin D (1 µM), which binds to 
the barbed end of F-actin to prevent the addition of G-actin monomers (Cingolani and 
Goda, 2008), for 1 hour prior to and during treatment with Tat. Cytochalasin D did not 
affect Tat-induced NMDAR potentiation by 16 h, but did prevent the reduction of 
NMDA-evoked [Ca2+]i responses observed after 24 h treatment with Tat (Fig. 3.4 c, d). 
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Additionally, cultures were pretreated with phalloidin (1 µM), which binds to and 
stabilizes F-actin polymers (Cingolani and Goda, 2008), for 1 hour prior to and during 
treatment with Tat. Phalloidin did not affect Tat-induced NMDAR potentiation by 16 h, 
but did block adaptation of NMDA-evoked [Ca2+]i responses after 24 h treatment with 
Tat (Fig. 3.4 e, f). These data suggest that Tat-induced reorganization of the actin 
cytoskeleton reduces NMDA-evoked [Ca2+]i responses. 
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Figure 3.4: Adaptation of NMDAR function requires remodeling of the actin 
cytoskeleton 
a, c, e, Representative traces show NMDA-evoked [Ca2+]i increases from control  ( ) 
neurons or neurons treated with 50 ng/mLTat ( ) for 16 h or 24 h. Cells were pretreated 
with ML-7 (10 µM), Cytochalasin D (CyD, 1 µM), or Phalloidin (Phal, 1 µM) for 1 h 
prior to the addition of Tat. NMDA (10 µM, 30 s) was applied by superfusion at the times 
indicated by the horizontal bars. b, d, f, bar graphs show net [Ca2+]i increase evoked by 
10 µM NMDA in control (  ) cells or cells treated with Tat (  ) for 16 h or 24 h. Cells 
were pretreated with ML-7, CyD, or Phal as indicated. ****p<0.0001 relative to 
respective control; ‡‡‡‡p<0.0001 relative to untreated control within timepoint; 
####p<0.0001 relative to 24 h Tat-treated neurons as determined by separate, one-way 
ANOVAs with 4 levels per treatment time followed by Tukey’s post-test for multiple 
comparisons.  
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Because phalloidin and cytochalasin D have opposing effects on the actin 
cytoskeleton, but similarly prevented adaptation, we further examined the effects of actin 
polymerization and depolymerization on the neuronal distribution of actin and NMDA-
evoked responses. To examine the effects of these agents on the actin cytoskeleton, 
neurons were cotransfected with plasmids encoding EGFP-Actin and Tag-RFP; cultures 
were then treated for 1 h with jasplakinolide  (10 µM), which promotes F-actin 
polymerization, or latrunculin A (5 µM), which sequesters G-actin to promote F-actin 
depolymerization (Cingolani and Goda, 2008). Treatment for 1 h with jasplakinolide 
induced robust somatic and dendritic redistribution of the actin cytoskeleton and caused 
retraction of dendritic spines (Fig. 3.5 a). Latrunculin A dispersed the actin cytoskeleton, 
revealed fibers in the neuronal cell body, and caused a dramatic loss of dendritic spines 
(Fig. 3.5 b). To determine if changes in the actin cytoskeleton affect NMDAR function, 
cultures were treated for 1 h to 24 h with jasplakinolide (10 µM) or latrunculin A (5 µM). 
Treatment with jasplakinolide attenuated NMDA-evoked [Ca2+]i responses as early as 1 
h. (Fig. 3.5 c, d). Treatment with latrunculin A also reduced NMDA-evoked [Ca2+]i 
responses, but required 24 h for significant functional impairment to develop (Fig. 3.5 c, 
d). Such rapid and persistent changes to the actin cytoskeleton caused by Jasplakinolide 
and Latrunculin A are consistent with previous reports (Okamoto et al., 2004) and 
indicate that bidirectional reorganization of actin reduces NMDAR function.  
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Figure 3.5: Reorganization of the actin cytoskeleton reduces NMDA-evoked [Ca2+]i 
responses  
a, b, Representative confocal images (Scale bar = 10 µm) of  neurons expressing EGFP-
Actin and Tag-RFP before (0 h) and after 1 h treatment with 10µM Jasplakinolide (a) or 
5 µM Latrunculin A (b). Compressed z-stacks of red (Tag-RFP) and green (EGFP-Actin) 
were superimposed. c, representative traces show NMDA-evoked [Ca2+]i increases from 
control  ( ) neurons or neurons treated with 10 µM jasplakinolide ( ) or 5 µM 
latrunculin A ( ) for the times indicated above the traces. NMDA (10 µM, 30 s) was 
applied by superfusion at the times indicated by the horizontal bars below the traces. d, 
plot summarizes time-dependent changes in NMDA-evoked [Ca2+]i increases from 
control  ( ) neurons and neurons treated with 10 µM jasplakinolide ( ) or 5 µM 
latrunculin A ( ).***p<0.001, ****p<0.0001 relative to control as determined by 
separate, one-way ANOVAs with 5 levels per treatment followed by Tukey’s post-test 
for multiple comparisons.  
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IV. Discussion  
NMDAR dysfunction contributes to the neurotoxicity that underlies many 
neurodegenerative disorders including HAND (Young et al., 1988; Danysz and Parsons, 
2003; Hallett and Standaert, 2004; Rossi et al., 2013; Spalloni et al., 2013). Although the 
neuropathogenesis of HAND likely involves a combination of factors, evidence suggests 
that the HIV protein Tat plays a prominent role by altering the activity of NMDARs 
(Haughey et al., 2001; Song et al., 2003; Chandra et al., 2005; Krogh et al., 2014) and 
impairing cognitive function (Fitting et al., 2010; Carey et al., 2012; Bachani et al., 
2013). Here we used digital Ca2+ imaging to study the pathways that modulate NMDA-
evoked [Ca2+]i responses during prolonged exposure to Tat. Previous work described a 
biphasic change in NMDA-evoked increases in [Ca2+]i during prolonged exposure to Tat.  
Initially, Tat potentiated NMDAR function via LRP-dependent activation of Src kinase; 
NMDAR function subsequently adapted after activation of the NOS/sGC/PKG pathway 
(Krogh et al., 2014). The goal of this study was to identify effectors downstream of PKG 
responsible for adaptation of NMDA-evoked responses following Tat-induced NMDAR 
potentiation. We determined that a RhoA/ROCK-dependent remodeling of the actin 
cytoskeleton was an obligatory step in NMDAR adaptation (Fig. 3.6). Adaptation of 
NMDAR function may be a neuroprotective mechanism to prevent excessive NMDAR-
mediated Ca2+ influx. 
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Figure 3.6: Proposed mechanism of Tat-induced biphasic change in NMDAR 
function. 
HIV-1 Tat interacts with LRP leading to Src-dependent potentiation of the NMDAR and 
activation of the NOS/sGC/PKG signaling pathway. PKG activates a RhoA/ROCK 
signaling pathway leading to remodeling of the actin cytoskeleton and subsequent 
reduction of NMDAR function.  
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The small GTPase RhoA is a well-known regulator of the actin cytoskeleton 
(Kaibuchi et al., 1999). The expression and function of RhoA is regulated by NO-
mediated activation of PKG in vascular smooth muscle cells (Sauzeau et al., 2003; Rolli-
Derkinderen et al., 2005) consistent with our hypothesis that Tat activates a 
NOS/sGC/PKG signaling cascade upstream from RhoA. Tat activates RhoA in 
endothelial cells (Urbinati et al., 2005; Yuen et al., 2010; Zhong et al., 2010; Xu et al., 
2012), however much less is known about the effects of Tat on RhoA in neurons. Our 
data show that adaptation of NMDAR function following Tat-induced potentiation 
required activation of RhoA. Pharmacologic or genetic inhibition of RhoA prevented 
adaptation of NMDAR function following Tat-induced potentiation. Furthermore, 
constitutive activation of RhoA attenuated NMDA-evoked responses by approximately 
50% relative to non-expressing neurons in the same imaging field, consistent with our 
hypothesis that RhoA activation reduces NMDAR function. Thus, Tat-induced activation 
of RhoA attenuates NMDAR function. Because inhibition of RhoA had no effect on 
NMDA-evoked responses until the cell had been treated with Tat for over 8 h, we 
speculate that the adaptive response is a mechanism to compensate for the excess Ca2+ 
influx resulting from potentiation of NMDARs.  
Activation and inhibition of RhoA profoundly affected neuronal morphology. 
Consistent with previous reports (Da Silva et al., 2003; Chen and Firestein, 2007), 
neurons expressing DN-RhoA exhibited increased dendritic branching while cells 
expressing CA-RhoA displayed simplified dendritic structures with minimal branching 
and no noticeable dendritic spines. Interestingly, activation of RhoA causes synapse loss 
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in vitro (Sunico et al., 2010) and loss of dendritic spines resulting in cognitive 
impairment in vivo (Pozueta et al., 2013). Similarly, treatment with Tat causes synapse 
loss in vitro (Kim et al., 2008; Shin et al., 2012) and loss of dendritic spines resulting in 
cognitive impairment in vivo (Fitting et al., 2010; Carey et al., 2012). Whether RhoA 
activation is required for Tat-induced synaptodendritic changes in vivo remains unknown. 
ROCK is the primary downstream target of RhoA and is a serine/threonine kinase 
that modifies the cytoskeleton to regulate cell migration and proliferation (Matsui et al., 
1996; Amano et al., 2010). Tat increases expression of ROCK in endothelial cells of the 
blood brain barrier (Zhong et al., 2012) and activation of ROCK in neurons induces 
rundown of NMDAR currents via an actin-dependent mechanism (Beazely et al., 2008).  
Based on these studies, we hypothesized that Tat-induced activation of ROCK would 
attenuate NMDA-evoked responses. Consistent with our hypothesis, we show that 
inhibition of ROCK prevented adaptation of NMDAR function following Tat-induced 
potentiation. These data indicate that Tat-induced activation of ROCK reduces NMDAR 
function. Abnormal activation of ROCK is observed in many models of neuronal 
disorders including Alzheimer’s disease, spinal-cord injury, neuropathic pain, and 
excitotoxicity (Mueller et al., 2005). However, little is known about the role of ROCK in 
HAND. 
RhoA activates ROCK to regulate the actin cytoskeleton by acting on multiple targets 
including MLCK (Maekawa et al., 1999). We found that adaptation of NMDA-evoked 
responses did not require MLCK. Inhibition of MLCK with ML-7 significantly inhibited 
NMDAR function. These results are consistent with previous reports indicating that 
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MLCK regulates NMDAR activity by contraction of actomyosin (Lei et al., 2001), 
however the effector between ROCK and the actin cytoskeleton remains unknown.  
Activation of ROCK increases F-actin formation (Da Silva et al., 2003).  The status 
of F-actin polymerization affects NMDAR function. Indeed, depolymerization of the 
actin cytoskeleton reduces NMDAR-mediated currents (Rosenmund and Westbrook, 
1993) while polymerization of actin enhances glutamate receptor function (Furukawa et 
al., 1995). As anticipated, we found that F-actin depolymerization with latrunculin A 
reduced NMDAR function. Unexpectedly, increased F-actin polymerization with 
jasplakinolide also decreased NMDAR function.  Both jasplakinolide (Bubb et al., 1994) 
and CA-RhoA (Ishizaki et al., 1997) increase the formation of F-actin and both cause 
approximately 50% reduction in NMDAR function, suggesting that increased actin 
polymerization reduces NMDAR function. Although the mechanism leading to impaired 
NMDAR function remains unclear, there is precedent for modulation of NMDAR 
function through tension exerted on the NMDAR via its physical connection with the 
actin cytoskeleton (Lei et al., 2001).  Perhaps the robust somatic and dendritic 
redistribution of actin shown in Figure 3.5 disrupts the connections between the NMDAR 
and the actin cytoskeleton resulting in reduced NMDAR function.    
Adaptation of NMDAR function following Tat-induced potentiation was blocked by 
cytochalasin D and phalloidin, agents which inhibit polymerization and 
depolymerization, respectively (Cingolani and Goda, 2008).  These results suggest that 
adaptation occurs in response to remodeling of the actin cytoskeleton, an effect that 
requires both depolymerization and polymerization of actin. Tat is known to affect the 
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cytoskeleton; it depolymerizes actin in endothelial cells (Wu et al., 2004) and produces a 
loss of F-actin puncta in hippocampal neurons in vitro (Bertrand et al., 2014). Our data 
indicate that Tat activates a RhoA/ROCK pathway leading to remodeling of the actin 
cytoskeleton resulting in reduced NMDA-evoked responses.  
Adaptation of Tat-induced NMDAR potentiation might improve neuronal survival.  
However, increasing evidence suggests that over compensation following neuronal insult 
can lead to excessive inhibitory tone (Hargus and Thayer, 2013; Wu et al., 2014) and 
impaired connectivity due to lost excitatory synapses (Kim et al., 2008). Reduced 
NMDAR function during prolonged exposure to HIV neurotoxins may contribute to 
cognitive impairment analogous to the impairment seen in transgenic animals with 
reduced NMDAR expression (Tsien et al., 1996; Shimizu et al., 2000) or humans given 
NMDAR antagonists (Krystal et al., 1994; Malhotra et al., 1996).  Thus, inhibiting 
ROCK might prevent cognitive decline. Indeed, RhoA/ROCK are promising targets for 
treating various neurological disorders. ROCK inhibition lowers brain levels of amyloid-
β in a transgenic mouse model of Alzheimer’s disease (Zhou et al., 2003) and improves 
cognitive function in aged rats (Huentelman et al., 2009). Inhibition of ROCK also 
improves neurological function and reduces infarct size in models of ischemic stroke 
(Toshima et al., 2000; Satoh et al., 2001) and accelerates functional recovery from spinal 
cord injuries (Hara et al., 2000; Dergham et al., 2002; Fournier et al., 2003; Sung et al., 
2003; Tanaka et al., 2004). Thus, ROCK is a valuable drug target with neuroprotective 
and neuroregenerative potential. The ROCK inhibitor, fasudil, is a well-tolerated 
vasodilator that has been used clinically in Japan since 1995 for the treatment of 
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subarachnoid hemorrhage (Shibuya et al., 1992) and improves physical performance in 
patients with angina pectoris (Shimokawa et al., 2002). Importantly, fasudil is 
neuroprotective in models of Alzheimer’s disease (Song et al., 2013), amyotrophic lateral 
sclerosis (Takata et al., 2013), and Parkinson’s disease (Tonges et al., 2012). Whether 
fasudil or other ROCK inhibitors are effective against HAND remains to be determined.  
 In summary, we show that adaptation of NMDAR function following Tat-induced 
potentiation results from RhoA/ROCK-dependent remodeling of the actin cytoskeleton.  
These finding suggest that different signaling pathways mediate the neurotoxicity 
induced by HIV Tat over the course of prolonged exposure. As such, drugs that modulate 
ROCK signaling may warrant exploration as neuroprotective agents for the treatment of 
HAND. 
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Chapter Four: 
Concluding Remarks 
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I. Summary of current studies 
The studies described in this dissertation add novel temporal and molecular detail 
regarding the mechanisms affecting NMDAR function following exposure to the HIV-1 
protein, Tat. Tat-induced NMDAR potentiation is reported in multiple investigations, 
however many of the observations involve acute (min to h) effects of very high 
concentrations (up to 1500 ng/mL) of Tat that greatly exceed the concentration of Tat (up 
to 40 ng/mL) detected in the sera of HIV-infected patients (Xiao et al., 2000). In Chapter 
Two, it was demonstrated that 50 ng/mL Tat caused a biphasic change in NMDAR 
function over 48 hours. Tat initially potentiated NMDAR function following LRP-
dependent activation of Src kinase, which subsequently adapted by gradually returning to 
basal levels after activation of a NOS/sGC/PKG signaling pathway. In Chapter Three, 
effectors downstream of PKG responsible for reducing NMDAR function were 
identified. Tat activated a RhoA/ROCK signaling pathway resulting in actin remodeling 
and reduced NMDAR function. Adaptation of NMDAR function may be a novel 
neuroprotective mechanism to prevent Ca2+-induced neurotoxicity.  
 
II. Advantages and limitations of Ca2+ imaging 
Calcium imaging is a useful tool for the functional study many cell types including 
neurons. Ca2+-sensitive dyes allow accurate measurement of [Ca2+]i in live cells via 
imaging. Fura-2 is one of the most widely used ratiometric, Ca2+-sensitive dyes and has 
been a staple of Ca2+ imaging since 1985 (Grynkiewicz et al., 1985) receiving more than 
11,000 citations thus far. The use of ratiometric dyes is advantageous because the 
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measurement of [Ca2+]i is minimally affected by unequal probe loading, varying cell 
thickness, or dye leakage. Additionally, these Ca2+ indicators are bright at low 
intracellular concentrations thereby minimizing [Ca2+]i  buffering potential and are less 
susceptible to photobleaching compared with non-ratiometric indicators. Furthermore, 
this approach is non-invasive, does not disturb the cytoplasm, and leaves the cell 
membrane intact. Lastly, it is difficult to study ‘sick’ cells using other techniques, such as 
patch-clamping, but is easily achieved using Ca2+ imaging. These probes are available 
with wide-ranging affinities for Ca2+ and are attached to diverse chemical moieties for 
broad applicability. Ultimately, the properties of fura-2 and similar ratiometric Ca2+-
sensitive dyes result in enhanced experimental reproducibility. 
Despite the widespread popularity and broad applicability, Ca2+ imaging has several 
limitations. The use of chemical Ca2+ probes limits the duration of imaging. During 
extended imaging sessions, the Ca2+ probe is increasingly susceptible to 
compartmentalization and extrusion from the cell, which may negatively affect 
experimental recordings. Fortunately, several high molecular weight probes are available 
to prevent removal of the dye from the cell, but introduction of such large molecules into 
the cell requires microinjection or electroporation; challenging techniques to master. 
Another limitation is targeting the chemical Ca2+ indicator to organelles of interest or 
controlling the cellular localization. Genetically encoded Ca2+ indicators (GECIs) combat 
this limitation and allow expression and localization of fluorescent Ca2+-sensitive 
proteins to regions of interests. One such GECI, known as GCaMP, can be localized to 
the plasma membrane, post-synaptic densities, presynaptic terminals, or expressed 
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throughout the entire cell. Lastly, Ca2+ imaging does not precisely reflect the rate in 
intracellular Ca2+ signaling. Intracellular events can happen much faster than the Ca2+ 
probe is able to report, resulting in less-than-accurate quantification of Ca2+ signaling 
kinetics.  
Fortunately, the assay used for the studies outlined in this dissertation minimized 
many of the pitfalls of fura-2-based Ca2+ imaging by keeping imaging sessions brief and 
by studying the change in NMDA-evoked increases in [Ca2+]i in the neuronal cell body. 
In doing so, experimental reproducibility was maximized. However, this approach suffers 
from being unable to measure changes in [Ca2+]i at the synapse. Additionally, it remains 
unknown if these in vitro observations correlate with changes observed in vivo.  Finally, 
it remains to be determined if changes in NMDAR function correlate with cognitive 
impairment. Although, if reduced NMDAR function following prolonged exposure to 
HIV neurotoxins is observed in vivo, then cognitive impairment similar to the impairment 
observed in humans given NMDAR antagonists (Krystal et al., 1994; Malhotra et al., 
1996) is a reasonable expectation.  
 
III. Future directions 
The most exciting discovery from the studies in this dissertation is that the NMDA 
receptor undergoes a biphasic change in function. Potentiation of NMDAR function has 
been described in many reports since the 1980’s, however adaptation following NMDAR 
potentiation has not been previously described. The mechanisms regulating NMDAR 
adaptation may be just as important to the progression of disease as NMDAR 
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potentiation. Thus, a better understanding of the mechanisms regulating NMDAR 
adaptation may provide insight into the pathophysiology of certain diseases.  
Moving forward it will be important to determine if the biphasic change in NMDAR 
function measured in the neuronal cell body also occurs at the synapse.  Cognitive 
impairment in patients with HAND correlates with synaptodendritic changes. Thus, a 
logical next step will be to determine if Tat causes biphasic changes in synaptic NMDAR 
function. NMDAR subtypes GluN2A and GluN2B localize to synaptic and extrasynaptic 
regions, respectively and activate distinct intracellular signaling pathways (Hardingham 
and Bading, 2010). Although the studies outlined in this dissertation indicate that 
GluN2A is not involved in NMDAR adaptation following exposure to Tat, synaptic 
measurements may reveal exciting differences.  
A logical next step in determining the relevance of the current studies and in 
identifying therapeutic targets for HAND is to determine if Tat-induced activation of 
signaling pathways in vitro translates in an in vivo model.  Currently, the Thayer lab is 
working with a transgenic mouse model with inducible Tat expression.  This transgenic 
mouse model is reported to have cognitive shortcomings, but the precise mechanism 
leading to such impairment is unknown. Perhaps, Tat-induced activation of the signaling 
pathway outlined in this dissertation is involved, and pharmacologic blockade of the 
proposed therapeutic targets can prevent Tat-induced cognitive decline.  
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IV. Therapeutic potential of targeting the NMDA receptor 
More than 35 million of people suffer from neurodegenerative diseases worldwide 
(Mayeux, 2003; Prince et al., 2013). The prevalence and economic cost for many of these 
diseases are estimated to triple by the year 2050 (Prince et al., 2013). Unfortunately, 
effective treatment options for neurodegeneration are rare. Consequently, millions of 
patients are in desperate need for effective, next-generation pharmacotherapeutics. 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral 
sclerosis, multiple sclerosis, and HAND are etiologically distinct, but share a common 
pathway leading to neuronal injury: NMDA receptor dysfunction.  This dissertation 
describes how the HIV-1 protein Tat causes a biphasic change in NMDAR function. An 
enhanced understanding of the mechanisms leading to NMDAR dysfunction may help to 
guide the development of targeted therapeutics for the treatment of HAND and other 
neurodegenerative diseases.  
There is enormous potential for the treatment of neurodegenerative diseases by 
targeting the NMDA receptor. As such, scientists have eagerly pursued agents that 
selectively target the NMDAR for therapeutic benefit since the 1980s. It was not until 
recently that this fervor began to yield a small number of clinically approved drugs. Such 
a slow pace of development is indicative of the level of difficulty regarding the creation 
of safe and effective compounds that target the NMDAR. Excessive antagonism of the 
NMDAR results in hallucinations and sedation thereby precluding the use of most 
NMDAR antagonists in patients, while insufficient blockade lacks therapeutic benefit. 
Thus, the ideal NMDAR antagonist should allow normal neurotransmission to occur 
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while inhibiting excessive NMDAR activation. Memantine is a drug that possesses these 
qualities and is FDA-approved for temporary symptomatic relief in patients suffering 
from Alzheimer’s disease. Memantine is an uncompetitive NMDAR antagonist with 
inhibitory action that is contingent upon prior activation of the receptor. Thus, memantine 
only inhibits the NMDAR when it is overactivated. Intriguingly, memantine is useful 
against Tat-induced neurotoxicity; it prevents Tat-induced cell death and promotes the 
recovery of excitatory synapses after Tat-induced synapse loss has occurred (Shin et al., 
2012). Unfortunately, a clinical trial concluded that memantine had no effect on cognitive 
performance in HAND patients (Schifitto et al., 2007b; Zhao et al., 2010). Furthermore, 
memantine only provides symptomatic relief from Alzheimer’s disease for up to 6 
months and fails to prevent disease progression. Ideally, compounds generated in the 
future will be well tolerated, provide symptomatic relief, and prevent disease progression.  
Adaptation of NMDAR function following prolonged exposure to HIV neurotoxins 
may be a compensatory measure that allows neurons to adapt to a neurotoxic 
environment resulting in improved neuronal survival. However, overcompensation 
following neuronal insult can lead to impaired NMDAR function (Krogh et al., 2014). 
Reduced NMDAR function impairs cognitive performance in humans (Krystal et al., 
1994; Malhotra et al., 1996). Thus, drugs outlined in this dissertation that prevented the 
reduction of NMDAR function may be valuable agents for the prevention of HIV-
associated cognitive decline. ROCK has been shown to be a promising target for the 
treatment of various neurological disorders (Mueller et al., 2005). Inhibition of ROCK 
with a drug used in this dissertation, Y27632, reduces levels amyloid-β in transgenic and 
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cell culture-based models of Alzheimer’s disease (Zhou et al., 2003). Inhibition of ROCK 
also improves learning and memory in aged rats (Huentelman et al., 2009), and improves 
neurological deficits following acute cerebral ischemia (Toshima et al.; Satoh et al.). 
Additionally, ROCK inhibition is neuroprotective against excitotoxicity (Kitaoka et al., 
2004) and prevents neuropathic pain (Inoue et al., 2004). Lastly, inhibition of ROCK 
accelerates the functional recovery of spinal-cord injury in rodent models (Hara et al., 
2000; Dergham et al., 2002; Fournier et al., 2003; Sung et al., 2003; Tanaka et al., 2004). 
Thus, ROCK inhibitors have great potential as neuroprotective agents. The ROCK 
inhibitor fasudil is a well-tolerated and clinically approved drug indicated for the 
treatment of subarachnoid hemorrhage (Shibuya and Douglas, 1992).  Intriguingly, 
fasudil protects against neurodegeneration in models of ALS (Takata et al., 2013), 
Parkinson’s disease (Tonges et al., 2012), and Alzheimer’s disease (Song et al., 2013). 
Despite such promising reports, it remains unknown if the neuroprotective capabilities of 
fasudil will be applicable against HIV-associated neurotoxicity. However, targeting 
ROCK may be an indirect way to influence NMDAR function while bypassing the 
unwanted side effects that arise from directly targeting the NMDAR. While the NMDAR 
is an important target to prevent HIV-associated neurotoxicity, it is likely that combined 
approaches may yield the most favorable results. For instance, administration of cART 
with enhanced penetrance into the CNS combined with adjunctive therapy that indirectly 
targets the NMDAR may be an effective approach to reduce the symptoms of HAND 
while minimizing unwanted side effects.  Targeting the NMDAR will continue to be 
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challenging, but if done successfully has the potential to help millions of patients 
suffering from neurodegenerative diseases including HAND. 
In conclusion, the number of patients with neurodegenerative disorders and the cost 
of treatment are projected to skyrocket within the next 35 years and effective treatment 
options are scarce. NMDAR dysfunction contributes to the progression of many 
neurodegenerative diseases including HAND. In order to develop next-generation 
pharmacotherapeutics, an enhanced understanding of the pathways leading to NMDAR-
mediated neurotoxicity is required. The studies outlined in this dissertation provide 
molecular and temporal detail of NMDAR dysfunction following exposure to the HIV-1 
protein, Tat. Thus, the pathways described in this dissertation may provide insight into 
the development of new therapies for the treatment of HAND and other 
neurodegenerative diseases.  
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